Original Article
Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin
N Engl J Med 1997; 337:295-300July 31, 1997
- Abstract
Background
We conducted a randomized, prospective trial comparing external irradiation with external irradiation plus goserelin (an agonist analogue of gonadotropin-releasing hormone that reduces testosterone secretion) in patients with locally advanced prostate cancer.
Methods
From 1987 to 1995, 415 patients with locally advanced prostate cancer were randomly assigned to receive radiotherapy alone or radiotherapy plus immediate treatment with goserelin. The patients had a median age of 71 years (range, 51 to 80). Patients in both groups received 50 Gy of radiation to the pelvis over a period of five weeks and an additional 20 Gy over an additional two weeks as a prostatic boost. Patients in the combined-treatment group received 3.6 mg of goserelin (Zoladex) subcutaneously every four weeks starting on the first day of irradiation and continuing for three years; those patients also received cyproterone acetate (150 mg orally per day) during the first month of treatment to inhibit the transient rise in testosterone associated with the administration of goserelin.
Results
Data were available for analysis on 401 patients. The median follow-up was 45 months. Kaplan–Meier estimates of overall survival at five years were 79 percent (95 percent confidence interval, 72 to 86 percent) in the combined-treatment group and 62 percent (95 percent confidence interval, 52 to 72 percent) in the radiotherapy group (P = 0.001). The proportion of surviving patients who were free of disease at five years was 85 percent (95 percent confidence interval, 78 to 92 percent) in the combined-treatment group and 48 percent (95 percent confidence interval, 38 to 58 percent) in the radiotherapy group (P<0.001).
Conclusions
Adjuvant treatment with goserelin, when started simultaneously with external irradiation, improves local control and survival in patients with locally advanced prostate cancer.
Media in This Article
Figure 1
Kaplan–Meier Estimate of Overall Survival.Figure 2
Kaplan–Meier Estimate of the Disease-free Interval.Article Activity
- Article
The role of external irradiation in patients with locally advanced prostate cancer is controversial.1,2 At this stage of the disease the tumor extends beyond the capsule of the prostate; it may infiltrate neighboring structures and involve regional lymph nodes, but there are no distant metastases (stage T3–4, N0–2, M0, according to the tumor–node–metastasis [TNM] classification system of the International Union against Cancer). In a study begun in 1973, the overall survival after 15 years for 287 patients with locally advanced prostate cancer who were treated with conventional external irradiation was 23 percent.3 Achieving local control after radiotherapy improved the prognosis; among patients who did not have involvement of regional lymph nodes at the time of diagnosis, 70 percent of those who attained local control survived for 20 years free of distant metastases, as compared with 13 percent of those who had a local relapse (P<0.001).4
Hormonal therapy often prolongs the suppression of the primary tumor by radiotherapy,5 but the question remains whether hormonal therapy should be reserved for relapse or used early in asymptomatic patients with locally advanced disease who are receiving external radiation treatment. Three controlled clinical trials have failed to demonstrate the value of prophylactic therapy with diethylstilbestrol, orchiectomy, or both in patients treated with external radiotherapy.6-8 A study of 277 patients found no differences among those undergoing orchiectomy, radiotherapy, or combined treatment; orchiectomy, however, whether alone or combined with radiotherapy, significantly delayed metastases as compared with radiotherapy alone.9
Goserelin is an agonist analogue of gonadotropin-releasing hormone that induces hypogonadism by reducing the secretion of gonadotropin and therefore testosterone. The purpose of this trial was to determine whether treatment with goserelin, when initiated during the first week of irradiation, increases disease-free survival and prolongs overall survival in patients at high risk for metastatic prostate cancer.
Methods
Eligibility Criteria
Patients were eligible if they were under 80 years of age, with histologically proved prostatic adenocarcinoma that was intracapsular (T1) or confined to the gland (T2), without detectable involvement of regional lymph nodes (N0-X), and of World Health Organization (WHO) histologic grade 3; or if they had prostate cancer of any histologic grade that extended beyond the capsule (T3) or infiltrated neighboring structures (T4) without involving regional lymph nodes. The clinical evaluation included bone scanning, chest radiography, and ultrasonography or computed tomography (CT) of the liver. Lymph nodes were evaluated by CT, bipedal lymphangiography, or extraperitoneal lymphadenectomy. Laboratory studies included complete blood counts and measurements of creatinine, serum prostatic acid phosphatase, serum testosterone, and prostate-specific antigen (PSA), as assessed by radioimmunometric or immunoenzyme assays. Eligible patients had had no previous treatment for prostate cancer and gave written informed consent. Patients with a previous malignant disease, except for treated basal-cell carcinoma of the skin, and those with evidence of distant metastases, including metastases to common iliac or paraaortic lymph nodes, were excluded. Pathological specimens were reviewed centrally.
Techniques of Treatment
Radiotherapy
Photons of 10 MV and above were recommended; when they were not available, the use of cobalt-60 was acceptable provided the skin-to-source distance was more than 80 cm and patients had a maximal anterior–posterior pelvic diameter of less than 22 cm. Planning target volume I was the whole pelvis, and planning target volume II the prostate and seminal vesicles. The whole pelvis was irradiated with a four-field technique, with one anterior–posterior field, one posterior–anterior field, and two parallel opposed lateral fields. In the craniocaudal direction the upper limit was the L5–S1 interspace, the lower limit was the ischial tuberosities, and the lateral margins were 1 cm beyond the maximal width of the bony pelvis; some centers preferred to irradiate a smaller target volume by using anterior–posterior fields averaging 12 by 12 cm and lateral fields averaging 12 by 10 cm. Planning target volume II was irradiated with either the same technique or with three fields: one anterior–posterior and two lateral fields with wedge filters. The anterior and posterior security margins on the lateral fields were at least 2 cm. The specification of the dose was given at the intersection of the beam axes according to Report 29 of the International Commission on Radiation Units and Measurements.10 The dose per fraction was 2 Gy. Patients were treated once a day, five days a week, for seven weeks; planning target volume I was irradiated during a five-week period with up to 50 Gy, and planning target volume II was treated during the last two weeks with an additional 20 Gy.
Hormonal Treatment
Goserelin (Zoladex, Zeneca-Pharma) was supplied by the manufacturer in a disposable syringe loaded with 3.6 mg of the drug and fitted with a 16-gauge needle. The drug was administered subcutaneously every four weeks, starting on the first day of pelvic irradiation and continuing for three years; 150 mg of a steroidal antiandrogen, cyproterone acetate (Androcur, Schering), was given orally for one month, starting one week before the first dose of goserelin, to inhibit the transient rise of testosterone caused by goserelin.
Toxicity
Acute side effects of radiotherapy were scored according to the WHO scale.11 Late toxicity was scored according to the Radiotherapy Oncology Group scale: 0, no symptoms; 1, minor transient symptoms; 2, distressing, persistent, or recurring symptoms requiring occasional prolonged medical treatment; 3, symptoms requiring prolonged medical treatment, surgical intervention, or both; or 4, fatal complications. For patients receiving goserelin, adverse reactions were registered as hot flashes and gynecomastia. There was no quality-of-life study.
Assessment of Progression
Local failure was defined as an increase of more than 50 percent in the product of the two maximal perpendicular diameters of the primary lesion as measured digitally, by CT or transabdominal ultrasonography; in case of doubt, biopsy was highly recommended. Local progression was defined as the recurrence of a palpable tumor after initial regression. Regional failure, in the pelvic or paraaortic lymph-node areas, was demonstrated by ultrasonography or CT and was confirmed by biopsy. Distant metastases in bones, parenchymal organs, or soft tissues were identified radiologically and then by biopsy if deemed necessary.
Quality Assurance
The calibration of every linear accelerator was obtained by mailed thermoluminescence dosimetry checks. Individual clinical, biologic, pathological, and follow-up procedures for the main participating centers were reviewed individually to reconcile discrepancies between local data and data registered at the European Organization for Research and Treatment of Cancer (EORTC) Data Center. Protocol compliance was checked by a dummy-run procedure to evaluate differences in the definition of target volume, in treatment technique, and in dose specification and homogeneity.12
End Points and Statistical Analysis
Overall survival was measured from the date of randomization to the date of death or the most recent follow-up. The disease-free interval was measured from the date of randomization to the date of local or regional failure, the first appearance of distant metastases, or the last follow-up, whichever occurred first. The time until the first treatment failure after a biologic response was measured from the date of randomization to the date of clinically determined progression, PSA-determined progression, or the most recent follow-up; PSA-determined progression was defined as a PSA level greater than 1.5 ng per milliliter and increasing on two consecutive measurements.
The protocol was designed to detect a minimal increase from 40 percent to 55 percent in the 5-year disease-free rate, corresponding to an increase from 3.8 to 5.8 years in the median disease-free interval (assuming exponential distribution). To detect this difference, 75 patients in each treatment group had to be followed until relapse (α = 0.05, β= 0.2). Survival curves were estimated by using the Kaplan–Meier technique.13 All comparisons were made by means of a two-sided log-rank test with a 0.05 significance level.14 Data were analyzed according to the intention-to-treat principle.
Randomization
Randomization was centralized at the EORTC Data Center. Patients were stratified according to institution, the clinical stage of the disease, the results of extraperitoneal pelvic lymph-node biopsy, and the irradiation technique. The randomization was performed by the minimization technique.15
Results
Characteristics of the Patients
From May 1987 through September 1995, 415 patients entered the study — 208 in the pelvic-radiotherapy group and 207 in the combined-treatment group. The median duration of follow-up was 45 months. At the time of analysis, all but 14 patients had been evaluated. For the analysis, these 14 patients were considered eligible. Ten patients — six in the radiotherapy group and four in the combined-treatment group — were ineligible because of bone metastases (two patients), paraaortic lymph-node metastases (one), thrombocytopenia (one), inappropriate clinical stages (T1G1, one; T2G1, one; and T2G2, three; and T2 without mention of grade, one). The two groups of patients were well balanced with regard to age, WHO performance status, clinical stage, presence or absence of pelvic lymph-node metastases, WHO histologic grade, Gleason grade, serum acid phosphatase level, and base-line PSA level (Table 1Table 1
Age, Performance Status, WHO Grade, Gleason Score, and Tumor and Node Classification among Patients Eligible for the Trial.). Cardiovascular disease was present in 29 percent of the patients in the radiotherapy group and 24 percent of those in the combined-treatment group; no chronic disease was mentioned for 48 percent of the patients in the radiotherapy group as compared with 53 percent in the combined-treatment group.Compliance
Information about treatment was available for 401 patients — 198 in the radiotherapy group and 203 in the combined-treatment group. Of the patients in the radiotherapy group, 99 percent received external irradiation; 80 percent of these patients received large-field and 20 percent small-field radiotherapy. Three of the 198 patients refused the treatment.
Of the 203 patients in the combined-treatment group, 2 refused any treatment and 6 refused hormonal therapy. At the time of analysis, not all the patients in this group had completed the three-year treatment with goserelin, but 15 patients continued that treatment for more than three years (Table 2Table 2
Compliance with the Goserelin Regimen among 195 Patients in the Combined-Treatment Group.). Eighty-one percent of the patients in this group received large-field and 19 percent small-field radiotherapy.Toxicity
Of the acute toxic effects listed in Table 3Table 3
Grade 3 or 4 Toxic Effects Reported during Radiotherapy among All Eligible Patients Who Underwent Radiotherapy., none with a grade of 3 or 4 affected more than 5 percent of either group except for diarrhea. With a median follow-up of 45 months, not more than 1 percent of either group had grade 3 late toxic effects, including hematuria, chronic diarrhea, proctitis, cystitis, small-bowel obstruction, incontinence, and urethral stricture. Data on erectile function were not collected systematically. Among the patients receiving goserelin, 62 percent had hot flashes, but only 34 percent had more than three per day. During follow-up, more patients in the combined-treatment group than in the radiotherapy group had late grade 1–3 incontinence (29 percent vs. 16 percent, P = 0.002); the proportions of patients with late grade 1–3 urethral stricture (20 percent in the combined-treatment group vs. 13 percent in the radiotherapy group) were not significantly different (P = 0.09). Thirty-eight patients (19 percent) had adverse reactions to the gonadotropin-releasing hormone analogue: hot flashes (22 patients), gynecomastia (4), mastodynia (1), breast pain and galactorrhea (1), sweating (2), weakness (2), depression (1), deep venous thrombosis (1), and unspecified reactions (4).Efficacy
The Kaplan–Meier estimate of overall survival at five years in the combined-treatment group was 79 percent (95 percent confidence interval, 72 to 86 percent), as compared with 62 percent (95 percent confidence interval, 52 to 72 percent) in the radiotherapy group (P = 0.001) (Figure 1Figure 1
Kaplan–Meier Estimate of Overall Survival.). For overall survival, the hazard ratio was 0.50 (95 percent confidence interval, 0.33 to 0.76). There were 58 deaths in the radiotherapy group and 35 in the combined-treatment group. Of these deaths, 26 in the radiotherapy group and 6 in the combined-treatment group were due to prostate cancer. Among the patients who survived for five years, the disease-free rate was 85 percent (95 percent confidence interval, 78 to 92 percent) in the combined-treatment group and 48 percent (95 percent confidence interval, 38 to 58 percent) in the radiotherapy group (hazard ratio = 0.22; 95 percent confidence interval, 0.15 to 0.32; P<0.001) (Figure 2Figure 2Kaplan–Meier Estimate of the Disease-free Interval.). Seventy-eight patients had disease progression in the radiotherapy group, as compared with 20 in the combined-treatment group. Table 4Table 4
Sites of Disease Progression. shows the sites of progression. In the radiotherapy group, the treatment given after progression included goserelin in 56 cases (72 percent) and another hormonal treatment in 17 cases and was unspecified in 5 cases. The 17 other treatments were orchiectomy (eight patients), another hormonal treatment (two), delayed treatment (five), and no treatment, because of intercurrent death (one) and the patient's refusal (one). The five-year local-control rate was 97 percent in the combined-treatment group and 77 percent in the radiotherapy group (hazard ratio = 0.19; 95 percent confidence interval, 0.10 to 0.37; P<0.001). The combined-treatment group had a longer time until the first treatment failure after a biologic response than the radiotherapy group (6.6 years [95 percent confidence interval, 3.5 to 5.3] vs. 4.4 years [95 percent confidence interval, 5.8 to 9.0]; hazard ratio = 0.17; 95 percent confidence interval, 0.11 to 0.48; P< 0.001). The five-year failure-free rate after biologic response was 81 percent for the combined-treatment group and 43 percent for the radiotherapy group.Discussion
We found that adjuvant therapy with an analogue of gonadotropin-releasing hormone (goserelin), started at the beginning of external irradiation treatment and continuing for three years, can improve the five-year overall survival of patients with locally advanced prostate cancer. Two previous studies have compared short-term hormonal therapy before and during external irradiation, or long-term hormonal therapy after external irradiation, with radiation therapy alone for locally advanced prostatic carcinoma. The hormonal therapy included flutamide and goserelin for the former and goserelin alone for the latter; both protocols showed advantages over radiotherapy alone in terms of local control, the incidence of distant metastases, and progression-free survival.16,17 However, it is difficult to compare these three trials, since the eligibility criteria, the timing and duration of administration of goserelin, the definition of local control, and the results in the radiotherapy groups are not quite comparable. In our study, we assessed local control by endorectal examination; a second biopsy of the prostate was not mandatory if the endorectal examination was normal, even if the serum PSA level was elevated. This aspect of assessment has been addressed previously, and one year after the completion of external irradiation the rate of positive biopsy results has been found to reach a plateau of 35 percent.18 The clinical results in our control group are in keeping with those of a retrospective analysis of 397 patients, with stage T3–T4 disease, who were treated only by external irradiation in 19 French institutes from 1983 to 1987. The rate of local control at five years was 79 percent, as compared with 77 percent (95 percent confidence interval, 68 to 86 percent) in the EORTC trial.19 The time until the first treatment failure after a biologic response is a surrogate end point that represents the time from randomization to the date of clinically determined progression or PSA-determined progression. Analysis using this end point showed a significant difference between combined treatment and radiotherapy alone (hazard ratio = 0.17; 95 percent confidence interval, 0.11 to 0.48; P<0.001).
We are indebted to Zeneca-Pharma for providing Zoladex and to F.W.J. Ten Kate, M.D., J. Mattelaer, M.D., J. Lopez Torrecilla, M.D., J.R. Pfeffer, M.D., C.L. Cutajar, M.D., T. Roberts, M.D., S. Fossa, M.D., J.C. Horiot, M.D., H. Hamers, M.D., J.F. Bossett, M.D., F. Kovner, M.D., H. Van Poppel, M.D., J. Jager, M.D., V. Svoboda, M.D., J.J. Zambon, M.D., J.J. Wijndaele, M.D., O. Koriakine, M.D., and C. Boekenkruger, M.D., for their collaboration.
Source Information
From University Hospital, Grenoble, France (M.B.); Akademisch Medisch Centrum, Amsterdam, the Netherlands (D.G.); Princess Margaret Hospital, Toronto (P.W.); Centre Régional de Lutte contre le Cancer Val d'Aurelle, Montpellier, France (J.B.D.); Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland (R.-O.M.); Oncologisch Centrum, Brussels (G.S.); Ospedale San Giovanni, Bellinzona, Switzerland (J.B.); Rambam Medical Center, Haifa, Israel (A.K.); Ufficio Sternberg & Pansadoro, Rome (C.S.); and the European Organization for Research and Treatment of Cancer Data Center, Brussels (T.G., L.C., M.P.).
Address reprint requests to Dr. Bolla at the Radiotherapy Department, University Hospital, B.P. 217 38043 Grenoble CEDEX 9, France.
Appendix
The following EORTC Radiotherapy Cooperative Group institutions participated in this study: Grenoble, Hôpital Albert Michallon; Montpellier, Centre Val d'Aurelle; Dijon, Centre Georges-François Leclerc; Besançon, Hôpital Jean Minjoz; Amsterdam, Akademisch Medisch Centrum; Heerlen, Radiotherapeutisch Instituut Limburg; Tilburg, B. Verbeeten Instituut; Lausanne, Centre Hospitalier Universitaire Vaudois; Bellinzona, Ospedale San Giovanni; Toronto, Princess Margaret Hospital; Haifa, Rambam Medical Hospital; Jerusalem, Hadassah University Hospital; Tel Aviv, Tel Aviv Medical Center–Ichilov Hospital; Valencia, Instituto Valenciano de Oncologia; and Portsmouth, St. Mary's Hospital.
The following EORTC Genitourinary Group institutions participated in this study: Maastricht, Akademisch Ziekenhuis; Rotterdam, Zuiderziekenhuis; Brussels, Akademisch Ziekenhuis; Kortrijk, St. Maarten Hospital; Leuven, Universitair Ziekenhuis Sint Rafael; Antwerp, Universitair Ziekenhuis; Rome, Ufficio Sternberg & Pansadoro; Malta, St. Luke's Hospital; Newcastle-upon-Tyne, Freeman Hospital; Obninsk, Medical Radiological Research Center; and Oslo, Norwegian Radium Hospital.
- References
References
1
Bagshaw MA, Cox RS, Ray GR. Status of radiation treatment of prostate cancer at Stanford University. In: Consensus Development Conference on the Management of Clinically Localized Prostate Cancer. National Cancer Institute monographs. No. 7. Washington, D.C.: Government Printing Office, 1988:47-60.
2
National Institutes of Health Consensus Development Panel. Consensus statement: the management of clinically localized prostate cancer. In: Consensus Development Conference on the Management of Clinically Localized Prostate Cancer. National Cancer Institute monographs. No. 7. Washington, D.C.: Government Printing Office, 1988:3-6.
3
Hanks GE ,Corn BW ,Lee WR ,Hunt M ,Hanlon A ,Schultheiss TE . External beam irradiation of prostate cancer: conformal treatment techniques and outcomes for the 1990s. Cancer 1995;75:1972-1977
CrossRef | Web of Science4
Leibel SA ,Fuks Z ,Zelefsky MJ ,Whitmore WF Jr . The effects of local and regional treatment on the metastatic outcome in prostatic carcinoma with pelvic lymph node involvement. Int J Radiat Oncol Biol Phys 1994;28:7-16
CrossRef | Web of Science | Medline5
Schröder FH. What is new in endocrine therapy of prostatic cancer? In: Newling DWW, Jones WG, eds. EORTC Genitourinary Group monograph 7. Prostate cancer and testicular cancer. New York: Wiley–Liss, 1990:45-52.
6
van der Werf-Messing B ,Sourek-Zikova V ,Blonk DI . Localized advanced carcinoma of the prostate: radiation therapy versus hormonal therapy. Int J Radiat Oncol Biol Phys 1976;1:1043-1048
CrossRef | Web of Science | Medline7
Neglia WJ ,Hussey DH ,Johnson DE . Megavoltage radiation therapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1977;2:873-883
CrossRef | Web of Science | Medline8
Taylor WJ ,Richardson RG ,Hafermann MD . Radiation therapy for localized prostate cancer. Cancer 1979;43:1123-1127
CrossRef | Web of Science | Medline9
Fellows GJ ,Clark PB ,Beynon LL , et al. Treatment of advanced localised prostatic cancer by orchiectomy, radiotherapy, or combined treatment: a Medical Research Council study. Br J Urol 1992;70:304-309
Medline10
ICRU report 29. Dose specification for reporting external beam therapy with photons and electrons. Washington, D.C.: International Commission on Radiation Units and Measurements, April 1, 1978.
11
WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization, 1979.
12
Dusserre A ,Garavaglia G ,Giraud JY ,Bolla M . Quality assurance of the EORTC radiotherapy trial 22863 for prostatic cancer: the dummy run. Radiother Oncol 1995;36:229-234
CrossRef | Web of Science | Medline13
Kaplan EL ,Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
CrossRef | Web of Science14
Mantel N . Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-170
Medline15
Pocock SJ ,Simon R . Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-115
CrossRef | Web of Science | Medline16
Pilepich MV ,Krall JM ,al-Sarraf M , et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995;45:616-623
CrossRef | Web of Science | Medline17
Pilepich MV ,Caplan R ,Byhardt RW , et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy. Prog Proc Am Soc Clin Oncol 1995;14:239-239 abstract.18
Scardino PT, Wheeler TM. Local control of prostate cancer with radiotherapy: frequency and prognostic significance of positive results of postirradiation prostate biopsy. In: Consensus Development Conference on the Management of Clinically Localized Prostate Cancer. National Cancer Institute monographs. No. 7. Washington, D.C.: Government Printing Office, 1988:95-103.
19
Rozan R, Albuisson E, Kin B, et al. External beam radiation of stage T3/T4 adenocarcinoma of the prostate. In: Bolla M, Rambeaud JJ, Vincent F, eds. Local prostatic carcinoma. Basel, Switzerland: Karger, 1994:98-110.
- Citing Articles (547)
Citing Articles
1
Douglas F. Beach, Robert A. Somer, Jean Hoffman-Censits, Jianqing Lin, Yu-Ning Wong, Elizabeth Plimeck, Gary Hudes, David Vaughn, Guy T. Bernstein, Gloria J. Morris. (2012) A Wealth of New Options: A Case Presentation of the Management of Castration-Recurrent Prostate Cancer. Seminars in Oncology 39:1, 1-8
CrossRef2
Jiri Kubeš, Cvek Jakub, Vondráček Vladimir, Dvořák Jan, Argalacsová Sona, Navrátil Matej, Buřil Jan. (2012) Results of combined radiotherapy and hormonal treatment of prostate cancer patients with initial PSA value >40ng/ml. Reports of Practical Oncology & Radiotherapy
CrossRef3
Roisin M Connolly, Michael A Carducci, Emmanuel S Antonarakis. (2012) Use of androgen deprivation therapy in prostate cancer: indications and prevalence. Asian Journal of Andrology
CrossRef4
Helmut Bonkhoff. (2012) Factors Implicated in Radiation Therapy Failure and Radiosensitization of Prostate Cancer. Prostate Cancer 2012, 1-12
CrossRef5
Ariel E. Marciscano, Matthew E. Hardee, Nicholas Sanfilippo. (2012) Management of High-Risk Localized Prostate Cancer. Advances in Urology 2012, 1-11
CrossRef6
S. G. Joniau, A. A. Van Baelen, C. Y. Hsu, H. P. Van Poppel. (2012) Complications and Functional Results of Surgery for Locally Advanced Prostate Cancer. Advances in Urology 2012, 1-8
CrossRef7
William T. Lowrance, Elena B. Elkin, David S. Yee, Andrew Feifer, Behfar Ehdaie, Lindsay M. Jacks, Coral L. Atoria, Michael J. Zelefsky, Howard I. Scher, Peter T. Scardino, James A. Eastham. (2011) Locally advanced prostate cancer: a population-based study of treatment patterns. BJU Internationalno-no
CrossRef8
Juan-Jie Bo, Chao Zhang, Lian-Hua Zhang, Ping Liu, Jian-Jun Sha, Jian-Wei Lv, Dong-Ming Liu, Yi-Ran Huang, Zheng Li. (2011) Androgen deprivation therapy through bilateral orchiectomy: increased metabolic risks. Asian Journal of Andrology 13:6, 833-837
CrossRef9
Murray Krahn, Karen E. Bremner, George Tomlinson, Jin Luo, Paul Ritvo, Gary Naglie, Shabbir M.H. Alibhai. (2011) Androgen deprivation therapy in prostate cancer: are rising concerns leading to falling use?. BJU International 108:10, 1588-1596
CrossRef10
William Y. Kim, Young E. Whang, Raj S. Pruthi, Maria Q. Baggstrom, W. Kimryn Rathmell, Julian G. Rosenman, Eric M. Wallen, Lav K. Goyal, Gayle Grigson, Catharine Watkins, Paul A. Godley. (2011) Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: A phase II trial. Urologic Oncology: Seminars and Original Investigations 29:6, 608-613
CrossRef11
Scott M. Gilbert, Yong-fang Kuo, Vahakn B. Shahinian. (2011) Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States. Urologic Oncology: Seminars and Original Investigations 29:6, 647-653
CrossRef12
S. Krause, K. Herfarth. (2011) Strahlentherapie des Prostatakarzinoms. Der Radiologe 51:11, 955-961
CrossRef13
Stephen S. Connolly, Paul J. Cathcart, Paul Gilmore, Michael Kerger, Helen Crowe, Justin S. Peters, Declan G. Murphy, Anthony J. Costello. (2011) Robotic radical prostatectomy as the initial step in multimodal therapy for men with high-risk localized prostate cancer: initial experience of 160 men. BJU Internationalno-no
CrossRef14
Padraig Warde, Malcolm Mason, Keyue Ding, Peter Kirkbride, Michael Brundage, Richard Cowan, Mary Gospodarowicz, Karen Sanders, Edmund Kostashuk, Greg Swanson, Jim Barber, Andrea Hiltz, Mahesh KB Parmar, Jinka Sathya, John Anderson, Charles Hayter, John Hetherington, Matthew R Sydes, Wendy Parulekar. (2011) Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. The Lancet
CrossRef15
Fred Saad. (2011) Prostate cancer therapy: finding the right balance. The Lancet Oncology
CrossRef16
H Payne, M Mason. (2011) Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments. British Journal of Cancer
CrossRef17
Sumanta Kumar Pal, Oliver Sartor. (2011) Current paradigms and Evolving concepts in metastatic castration-resistant prostate cancer. Asian Journal of Andrology 13:5, 683-689
CrossRef18
Richard Sullivan, Jeffrey Peppercorn, Karol Sikora, John Zalcberg, Neal J Meropol, Eitan Amir, David Khayat, Peter Boyle, Philippe Autier, Ian F Tannock, Tito Fojo, Jim Siderov, Steve Williamson, Silvia Camporesi, J Gordon McVie, Arnie D Purushotham, Peter Naredi, Alexander Eggermont, Murray F Brennan, Michael L Steinberg, Mark De Ridder, Susan A McCloskey, Dirk Verellen, Terence Roberts, Guy Storme, Rodney J Hicks, Peter J Ell, Bradford R Hirsch, David P Carbone, Kevin A Schulman, Paul Catchpole, David Taylor, Jan Geissler, Nancy G Brinker, David Meltzer, David Kerr, Matti Aapro. (2011) Delivering affordable cancer care in high-income countries. The Lancet Oncology 12:10, 933-980
CrossRef19
Jona A. Hattangadi, Ming-Hui Chen, Michelle H. Braccioforte, Brian J. Moran, Anthony V. D’Amico. (2011) Predictors of the use of supplemental androgen suppression therapy and external beam radiation in men with high-risk prostate cancer undergoing brachytherapy in community practice. Brachytherapy 10:5, 369-375
CrossRef20
Serge Ginzburg, Peter C. Albertsen. (2011) The Timing and Extent of Androgen Deprivation Therapy for Prostate Cancer: Weighing the Clinical Evidence. Endocrinology & Metabolism Clinics of North America 40:3, 615-623
CrossRef21
Amar U. Kishan, Ming-Hui Chen, Marian Loffredo, Dongsun Kim, Clair J. Beard, Mark D. Hurwitz, Neil E. Martin, Peter F. Orio, Philip W. Kantoff, Anthony V. D'Amico, Paul L. Nguyen. (2011) Low rate of clinician-scored gynecomastia induced by 6 months of combined androgen blockade in a randomized trial: Implications for prophylactic breast irradiation. Practical Radiation Oncology
CrossRef22
Paul R. Womble, Peter J. VanVeldhuizen, Alan A. Nisbet, Greg A. Reed, J. Brantley Thrasher, Jeffrey M. Holzbeierlein. (2011) A Phase II Clinical Trial of Neoadjuvant Ketoconazole and Docetaxel Chemotherapy Before Radical Prostatectomy in High Risk Patients. The Journal of Urology 186:3, 882-888
CrossRef23
Cyrille Bastide, Dominique Rossi, Eric Lechevallier, Franck Bladou, David Barriol, Denis Bretheau, Vincent Grisoni, Julien Mancini, Sophie Giusiano, Christophe Eghazarian, Antoine Van Hove. (2011) Seminal vesicle invasion: what is the best adjuvant treatment after radical prostatectomy?. BJU Internationalno-no
CrossRef24
Guillaume Ploussard, Pierre Mongiat-Artus. (2011) SEMINAL VESICLE INVASION: WHAT IS THE BEST ADJUVANT TREATMENT AFTER RADICAL PROSTATECTOMY?. BJU Internationalno-no
CrossRef25
Tracy L. Klayton, Karen Ruth, Eric M. Horwitz, Robert G. Uzzo, Alexander Kutikov, David Y.T. Chen, Mark Sobczak, Mark K. Buyyounouski. (2011) Young age under 60years is not a contraindication to treatment with definitive dose escalated radiotherapy for prostate cancer. Radiotherapy and Oncology
CrossRef26
Jones, Christopher U., Hunt, Daniel, McGowan, David G., Amin, Mahul B., Chetner, Michael P., Bruner, Deborah W., Leibenhaut, Mark H., Husain, Siraj M., Rotman, Marvin, Souhami, Luis, Sandler, Howard M., Shipley, William U., . (2011) Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer. New England Journal of Medicine 365:2, 107-118
Full Text27
Luke T. Lavallée, Victor M. Montori, Stephen E. Canfield, Rodney H. Breau. (2011) Advanced topics in evidence-based urologic oncology: Surrogate endpoints. Urologic Oncology: Seminars and Original Investigations 29:4, 447-453
CrossRef28
Mohamed Ismail, Matthew Ferroni, Leonard G. Gomella. (2011) Androgen Suppression Strategies for Prostate Cancer: Is There an Ideal Approach?. Current Urology Reports 12:3, 188-196
CrossRef29
P. Fourneret, Y. Benmati, M. Romanet, V. Beneyton, A. Tessier, J.-C. Bourre, P.-Y. Brard, M. Bolla. (2011) Prise en charge des cancers de la prostate : points de vue du radiothérapeute. Médecine Nucléaire 35:6, 360-367
CrossRef30
Paul L. Nguyen, Ming-Hui Chen, Joshua A. Beckman, Clair J. Beard, Neil E. Martin, Toni K. Choueiri, Jim C. Hu, Karen E. Hoffman, Daniel E. Dosoretz, Brian J. Moran, Sharon A. Salenius, Michelle H. Braccioforte, Philip W. Kantoff, Anthony V. D’Amico, Ronald D. Ennis. (2011) Influence of Androgen Deprivation Therapy on All-Cause Mortality in Men with High-Risk Prostate Cancer and a History of Congestive Heart Failure or Myocardial Infarction. International Journal of Radiation Oncology*Biology*Physics
CrossRef31
George Rodrigues, Kyounghwa Bae, Mack Roach, Colleen Lawton, Bryan Donnelly, David Grignon, Gerald Hanks, Arthur Porter, Herbert Lepor, Howard Sandler. (2011) Impact of Ultrahigh Baseline PSA Levels on Biochemical and Clinical Outcomes in Two Radiation Therapy Oncology Group Prostate Clinical Trials. International Journal of Radiation Oncology*Biology*Physics 80:2, 445-452
CrossRef32
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Rosenberg, Eric S., Cort, Alice M., Ebeling, Sally H.Peters, Christine C., Smith, Matthew R., Zietman, Anthony L., Finkelstein, Joel S., Wu, Chin-Lee, . (2011) Case 16-2011. New England Journal of Medicine 364:21, 2044-2051
Full Text33
James W Denham, Allison Steigler, David S Lamb, David Joseph, Sandra Turner, John Matthews, Chris Atkinson, John North, David Christie, Nigel A Spry, Keen-Hun Tai, Chris Wynne, Catherine D'Este. (2011) Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. The Lancet Oncology 12:5, 451-459
CrossRef34
Mei Lu, Svend O. Freytag, Hans Stricker, Jae Ho Kim, Kenneth Barton, Benjamin Movsas. (2011) Adaptive seamless design for an efficacy trial of replication-competent adenovirus-mediated suicide gene therapy and radiation in newly-diagnosed prostate cancer (ReCAP Trial). Contemporary Clinical Trials 32:3, 453-460
CrossRef35
Arne Solberg, Olav A. Haugen, Trond Viset, Anders Bergh, Ilker Tasdemir, Göran Ahlgren, Anders Widmark, Anders Angelsen. (2011) Residual Prostate Cancer in Patients Treated With Endocrine Therapy With or Without Radical Radiotherapy: A Side Study of the SPCG-7 Randomized Trial. International Journal of Radiation Oncology*Biology*Physics 80:1, 55-61
CrossRef36
Lars Budäus, Hartwig Huland, Markus Graefen. (2011) Controversies in the management of localized prostate cancer: Radical prostatectomy still the standard of care. Critical Reviews in Oncology/Hematology
CrossRef37
Lisa K. Morikawa, Mack Roach. (2011) Pelvic Nodal Radiotherapy in Patients With Unfavorable Intermediate and High-Risk Prostate Cancer: Evidence, Rationale, and Future Directions. International Journal of Radiation Oncology*Biology*Physics 80:1, 6-16
CrossRef38
Jonathan D. Grant, Mark S. Litwin, Lorna Kwan, Steve P. Lee, Michael L. Steinberg, Christopher R. King. (2011) Does Hormone Therapy Exacerbate the Adverse Effects of Radiotherapy in Men With Prostate Cancer? A Quality of Life Study. The Journal of Urology 185:5, 1674-1680
CrossRef39
Yu-hsiang Lin, Chien-lun Chen, Chen-pang Hou, Phei-lang Chang, Ke-hung Tsui. (2011) A comparison of androgen deprivation therapy versus surgical castration for patients with advanced prostatic carcinoma. Acta Pharmacologica Sinica 32:4, 537-542
CrossRef40
Ranko Miocinovic, Ryan K. Berglund, Andrew J. Stephenson, J. Stephen Jones, Amr Fergany, Jihad Kaouk, Eric A. Klein. (2011) Avoiding Androgen Deprivation Therapy in Men With High-risk Prostate Cancer: The Role of Radical Prostatectomy as Initial Treatment. Urology 77:4, 946-950
CrossRef41
Jochen Walz, Steven Joniau, Felix K. Chun, Hendrik Isbarn, Claudio Jeldres, Ofer Yossepowitch, Hsu Chao-Yu, Eric A. Klein, Peter T. Scardino, Alwyn Reuther, Hein Van Poppel, Markus Graefen, Hartwig Huland, Pierre I. Karakiewicz. (2011) Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy. BJU International 107:5, 765-770
CrossRef42
Mark D. Hurwitz, Jorgen L. Hansen, Savina Prokopios-Davos, Judith Manola, Qian Wang, Bruce A. Bornstein, Kullervo Hynynen, Irving D. Kaplan. (2011) Hyperthermia combined with radiation for the treatment of locally advanced prostate cancer. Cancer 117:3, 510-516
CrossRef43
Paul L. Nguyen, Ming H. Chen, Samuel Z. Goldhaber, Neil E. Martin, Clair J. Beard, Daniel E. Dosoretz, Michael J. Katin, Rudi Ross, Sharon A. Salenius, Anthony V D'Amico. (2011) Coronary revascularization and mortality in men with congestive heart failure or prior myocardial infarction who receive androgen deprivation. Cancer 117:2, 406-413
CrossRef44
C. Ferrandis, J.A. March, J.M. Martínez, J. Hernández, N. Diez, V. Morillo, F. García, P. Chuan. (2011) Combined external radiotherapy and hormone therapy in patients with locally advanced prostate cancer: Predictive factors of genitourinary toxicity. Actas Urológicas Españolas (English Edition) 35:3, 146-151
CrossRef45
Bhavin R. Shastri, Subhashini Yaturu. (2011) Metabolic Complications and Increased Cardiovascular Risks as a Result of Androgen Deprivation Therapy in Men with Prostate Cancer. Prostate Cancer 2011, 1-9
CrossRef46
Amitabh Chandra, David Cutler, Zirui Song. 2011. Who Ordered That? The Economics of Treatment Choices in Medical Care. , 397-432.
CrossRef47
Sejun Park, Seong Cheol Kim, Wansuk Kim, Cheryn Song, Hanjong Ahn. (2011) Impact of Adjuvant Androgen-Deprivation Therapy on Disease Progression in Patients with Node-Positive Prostate Cancer. Korean Journal of Urology 52:11, 741
CrossRef48
N. L. Keating. (2010) Medicare Reimbursement and Prescribing Hormone Therapy for Prostate Cancer. JNCI Journal of the National Cancer Institute 102:24, 1814-1815
CrossRef49
S. P. Elliott, S. L. Jarosek, T. J. Wilt, B. A. Virnig. (2010) Reduction in Physician Reimbursement and Use of Hormone Therapy in Prostate Cancer. JNCI Journal of the National Cancer Institute 102:24, 1826-1834
CrossRef50
Thomas Zilli, Miguel Chagnon, Thu Van Nguyen, Jean-Paul Bahary, Jean-Pierre Guay, Alix Dufresne, Daniel Taussky. (2010) Influence of abdominal adiposity, waist circumference, and body mass index on clinical and pathologic findings in patients treated with radiotherapy for localized prostate cancer. Cancer 116:24, 5650-5658
CrossRef51
Michel Bolla. (2010) Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward?. European Urology Supplements 9:11, 788-793
CrossRef52
Masato Sakamoto, Takashi Mizowaki, Michihide Mitsumori, Kenji Takayama, Keisuke Sasai, Yoshiki Norihisa, Toshiyuki Kamoto, Eijiro Nakamura, Osamu Ogawa, Masahiro Hiraoka. (2010) Long-term outcomes of three-dimensional conformal radiation therapy combined with neoadjuvant hormonal therapy in Japanese patients with locally advanced prostate cancer. International Journal of Clinical Oncology 15:6, 571-577
CrossRef53
Anthony V D'Amico. (2010) Is long-term androgen suppression right for everyone with locally advanced prostate cancer?. The Lancet Oncology 11:11, 1016-1017
CrossRef54
Michel Bolla, Jean Michel Hannoun-Levi, Jean-Marc Ferrero, Philippe Maingon, Joëlle Buffet-Miny, Agnès Bougnoux, Jacques Bauer, Jean-Luc Descotes, Philippe Fourneret, Florence Jover, Marc Colonna. (2010) Concurrent and adjuvant docetaxel with three-dimensional conformal radiation therapy plus androgen deprivation for high-risk prostate cancer: Preliminary results of a multicentre phase II trial. Radiotherapy and Oncology 97:2, 312-317
CrossRef55
Kazuhiko Ogawa, Katsumasa Nakamura, Tomonari Sasaki, Hiroshi Onishi, Masahiko Koizumi, Masayuki Araya, Nobutaka Mukumoto, Teruki Teshima, Michihide Mitsumori. (2010) Radical External Beam Radiotherapy for Clinically Localized Prostate Cancer in Japan: Changing Trends in the Patterns of Care Process Survey. International Journal of Radiation OncologyBiologyPhysics
CrossRef56
Bertrand Tombal. (2010) Prostate Cancer Management: What Does the Future Hold?. European Urology Supplements 9:8, 706-714
CrossRef57
Anne E. Kyrdalen, Alv A. Dahl, Eivor Hernes, Einar Hem, Sophie D. Fosså. (2010) Fatigue in prostate cancer survivors treated with definitive radiotherapy and LHRH analogs. The Prostate 70:13, 1480-1489
CrossRef58
Phillip M. Pierorazio, Thomas J. Guzzo, Misop Han, Trinity J. Bivalacqua, Jonathan I. Epstein, Edward M. Schaeffer, Mark Schoenberg, Patrick C. Walsh, Alan W. Partin. (2010) Long-term Survival After Radical Prostatectomy for Men With High Gleason Sum in Pathologic Specimen. Urology 76:3, 715-721
CrossRef59
Stacy Loeb, Edward M. Schaeffer, Bruce J. Trock, Jonathan I. Epstein, Elizabeth B. Humphreys, Patrick C. Walsh. (2010) What Are the Outcomes of Radical Prostatectomy for High-risk Prostate Cancer?. Urology 76:3, 710-714
CrossRef60
Supriya Gupta Mohile, Maureen Lacy, Miriam Rodin, Kathryn Bylow, William Dale, Michael R. Meager, Walter M. Stadler. (2010) Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer. Critical Reviews in Oncology/Hematology 75:2, 152-159
CrossRef61
R. Kvåle, B. Møller, A. Angelsen, O. Dahl, S.D. Fosså, O.J. Halvorsen, L. Hoem, A. Solberg, R. Wahlqvist, F. Bray. (2010) Regional trends in prostate cancer incidence, treatment with curative intent and mortality in Norway 1980–2007. Cancer Epidemiology 34:4, 359-367
CrossRef62
Michael Baumann, Tobias Hölscher, Jim Denham. (2010) Fractionation in prostate cancer – Is it time after all?. Radiotherapy and Oncology 96:1, 1-5
CrossRef63
Paul L. Nguyen, Ming-Hui Chen, Clair J. Beard, W. Warren Suh, Andrew A. Renshaw, Marian Loffredo, Elizabeth McMahon, Philip W. Kantoff, Anthony V. D'Amico. (2010) Radiation With or Without 6 Months of Androgen Suppression Therapy in Intermediate- and High-Risk Clinically Localized Prostate Cancer: A Postrandomization Analysis by Risk Group. International Journal of Radiation Oncology*Biology*Physics 77:4, 1046-1052
CrossRef64
Şefik İğdem, Gül Alço, Tülay Ercan, Metin Barlan, Kürşat Ganiyusufoğlu, Bülent Ünalan, Sedat Turkan, Sait Okkan. (2010) Insufficiency Fractures After Pelvic Radiotherapy in Patients With Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics 77:3, 818-823
CrossRef65
Basir Tareen, Joseph Kimmel, William C Huang. (2010) Contemporary treatment of high-risk localized prostate cancer. Expert Review of Anticancer Therapy 10:7, 1069-1076
CrossRef66
Vinod E Nambudiri, Nancy L Keating. (2010) Metabolic and cardiovascular risks of androgen-deprivation therapy for prostate cancer. Expert Review of Endocrinology & Metabolism 5:4, 531-537
CrossRef67
R.G.H.M. Cremers, H.E. Karim-Kos, S. Houterman, R.H.A. Verhoeven, F.H. Schröder, T.H. van der Kwast, P.J.M. Kil, J.W.W. Coebergh, L.A.L.M. Kiemeney. (2010) Prostate cancer: Trends in incidence, survival and mortality in the Netherlands, 1989–2006. European Journal of Cancer 46:11, 2077-2087
CrossRef68
Michael Myers, Priya Mitra, Mitchell Anscher, Anthony Addesa, Michael Hagan. 2010. Radiation Therapy for Clinically Localized Prostate Cancer. , 279-292.
CrossRef69
Chao-Yu Hsu, Mark F. Wildhagen, Hein Van Poppel, Chris H. Bangma. (2010) Prognostic factors for and outcome of locally advanced prostate cancer after radical prostatectomy. BJU International 105:11, 1536-1540
CrossRef70
Farhana Haseen, Liam J. Murray, Chris R. Cardwell, Joe M. O’Sullivan, Marie M. Cantwell. (2010) The effect of androgen deprivation therapy on body composition in men with prostate cancer: Systematic review and meta-analysis. Journal of Cancer Survivorship 4:2, 128-139
CrossRef71
Jason E Faris, Matthew R Smith. (2010) Metabolic sequelae associated with androgen deprivation therapy for prostate cancer. Current Opinion in Endocrinology, Diabetes and Obesity 17:3, 240-246
CrossRef72
Supriya Gupta Mohile, Maureen Lacy, Miriam Rodin, Kathryn Bylow, William Dale, Michael R. Meager, Walter M. Stadler. (2010) Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer. Journal of Geriatric Oncology 1:1, 13-19
CrossRef73
Steven C. Campbell, Nirmala Bhoopalam, Thomas E. Moritz, Mona Pandya, Padmini Iyer, Peter VanVeldhuizen, Nancy K. Ellis, Lizy Thottapurathu, Harinder Garewal, Stuart R. Warren, Nicholas Friedman, Domenic J. Reda. (2010) The Use of Zoledronic Acid in Men Receiving Androgen Deprivation Therapy for Prostate Cancer With Severe Osteopenia or Osteoporosis. Urology 75:5, 1138-1143
CrossRef74
Janet E. Brown, Jennifer M. Sherriff, Nicholas D. James. (2010) OSTEOPOROSIS IN PATIENTS WITH PROSTATE CANCER ON LONG-TERM ANDROGEN DEPRIVATION THERAPY: AN INCREASING, BUT UNDER-RECOGNIZED PROBLEM. BJU International 105:8, 1042-1043
CrossRef75
Joan Carles, Miguel Nogue, Josep M. Sole, Palmira Foro, Montserrat Domenech, Marta Suarez, Enrique Gallardo, Darío García, Ferrán Ferrer, Antoni Gelabert-Mas, Javier Gayo, Xavier Fabregat. (2010) Phase II Study of Vinorelbine and Estramustine in Combination With Conformational Radiotherapy for Patients With High-Risk Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics 76:4, 1085-1091
CrossRef76
William K. Oh, Mary Beth Landrum, Elizabeth B. Lamont, Barbara J. McNeil, Nancy L. Keating. (2010) Does Oral Antiandrogen Use Before Leuteinizing Hormone-releasing Hormone Therapy in Patients With Metastatic Prostate Cancer Prevent Clinical Consequences of a Testosterone Flare?. Urology 75:3, 642-647
CrossRef77
Xin Sun, Taiwei Chu, Xiangyun Wang. (2010) Preliminary studies of 99mTc-BnAO and its analogues: synthesis, radiolabeling and in vitro cell uptake. Nuclear Medicine and Biology 37:2, 117-123
CrossRef78
Jeanette Valero, Mauricio Cambeiro, Carlos Galán, Mercedes Teijeira, Pilar Romero, Javier Zudaire, Marta Moreno, Raquel Ciérvide, José Javier Aristu, Rafael Martínez-Monge. (2010) Phase II Trial of Radiation Dose Escalation With Conformal External Beam Radiotherapy and High-Dose-Rate Brachytherapy Combined With Long-Term Androgen Suppression in Unfavorable Prostate Cancer: Feasibility Report. International Journal of Radiation Oncology*Biology*Physics 76:2, 386-392
CrossRef79
Samdeep K. Mouli, Lee C. Zhao, Reed A. Omary, C. Shad Thaxton. (2010) Lymphotropic nanoparticle enhanced MRI for the staging of genitourinary tumors. Nature Reviews Urology 7:2, 84-93
CrossRef80
N. L. Keating, A. J. O'Malley, S. J. Freedland, M. R. Smith. (2010) Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate Cancer. JNCI Journal of the National Cancer Institute 102:1, 39-46
CrossRef81
Dalsan You, In Gab Jeong, Choung-Soo Kim. (2010) Role of Radical Prostatectomy for High-Risk Prostate Cancer. Korean Journal of Urology 51:9, 589
CrossRef82
Francesca Pistis, Ferran Guedea, Joan Pera, Cristina Gutierrez, Montse Ventura, Alfredo Polo, Evelyn Martinez, Ana Boladeras, Ferran Ferrer, Pietro Gabriele, Luis Linares. (2010) External beam radiotherapy plus high-dose-rate brachytherapy for treatment of locally advanced prostate cancer: The initial experience of the Catalan Institute of Oncology. Brachytherapy 9:1, 15-22
CrossRef83
Seth A. Rosenthal, Howard M. Sandler. (2010) Treatment strategies for high-risk locally advanced prostate cancer. Nature Reviews Urology 7:1, 31-38
CrossRef84
Daniel M. Moreira, Lionel L. Bañez, Joseph C. Presti Jr, William J. Aronson, Martha K. Terris, Christopher J. Kane, Christopher L. Amling, Stephen J. Freedland. (2010) Predictors of secondary treatment following biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database. BJU International 105:1, 28-33
CrossRef85
Dale R. Shepard, Derek Raghavan. (2010) Innovations in the systemic therapy of prostate cancer. Nature Reviews Clinical Oncology 7:1, 13-21
CrossRef86
Giuseppe Sasso, Aleksandra Zapotoczna, David Pryor, John Simpson. (2009) Magnetic resonance spectroscopy as a decision tool in multimodality treatment design for localised prostate cancer. Oncology Reviews 3:4, 215-223
CrossRef87
Jacques Planas, Enrique Trilla, Carles Ravent
s, Lluis Cecchini, Anna Orsola, Carles Salvador, Jose Placer, Gloria Encabo, Juan Morote. (2009) Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis. BJU International 104:11, 1637-1640
CrossRef88
Ayal A. Aizer, James B. Yu, Anne M. McKeon, Roy H. Decker, John W. Colberg, Richard E. Peschel. (2009) Whole Pelvic Radiotherapy Versus Prostate Only Radiotherapy in the Management of Locally Advanced or Aggressive Prostate Adenocarcinoma. International Journal of Radiation Oncology*Biology*Physics 75:5, 1344-1349
CrossRef89
Preetika Sharma, Amy Wisniewski, Milena Braga-Basaria, Xiaoqiang Xu, Mary Yep, Samuel Denmeade, Adrian S. Dobs, Theodore DeWeese, Michael Carducci, Shehzad Basaria. (2009) Lack of an Effect of High Dose Isoflavones in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy. The Journal of Urology 182:5, 2265-2273
CrossRef90
Ayal A. Aizer, James B. Yu, John W. Colberg, Anne M. McKeon, Roy H. Decker, Richard E. Peschel. (2009) Radical prostatectomy vs. intensity-modulated radiation therapy in the management of localized prostate adenocarcinoma. Radiotherapy and Oncology 93:2, 185-191
CrossRef91
Joaquim Bellmunt, Francesc Macià, Davide Malmusi, José A. Llorente, Joan Carles, Josep Lloreta, Palmira Foro, Antoni Gelabert, Joan Albanell, Xavier Castells. (2009) Impact of PSA implementation and combined radiation and hormonal therapy (RT+HT) on outcome of prostate cancer patients. European Journal of Cancer 45:16, 2804-2809
CrossRef92
Michael Pinkawa, Marc D Piroth, Karin Fischedick, Richard Holy, Jens Klotz, Sandra Nussen, Barbara Krenkel, Michael J. Eble. (2009) Impact of the Target Volume (Prostate Alone vs. Prostate with Seminal Vesicles) and Fraction Dose (1.8 Gy vs. 2.0 Gy) on Quality of Life Changes After External-Beam Radiotherapy for Prostate Cancer. Strahlentherapie und Onkologie 185:11, 724-730
CrossRef93
Christopher J. DiBlasio, John B. Malcolm, Jessica Hammett, Jim Y. Wan, Michael A. Aleman, Anthony L. Patterson, Robert W. Wake, Ithaar H. Derweesh. (2009) Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience. BJU International 104:9, 1208-1214
CrossRef94
Jonathan C. Picard, Ali-Reza Golshayan, David T. Marshall, Krisha J. Opfermann, Thomas E. Keane. (2009) The multi-disciplinary management of high-risk prostate cancer. Urologic Oncology: Seminars and Original Investigations
CrossRef95
Eric M. Horwitz. (2009) Prostate cancer: Optimizing the duration of androgen deprivation therapy. Nature Reviews Urology 6:10, 527-529
CrossRef96
Yu-Ning Wong, Stephen J. Freedland, Brian Egleston, Neha Vapiwala, Robert Uzzo, Katrina Armstrong. (2009) The Role of Primary Androgen Deprivation Therapy in Localized Prostate Cancer. European Urology 56:4, 609-616
CrossRef97
S. G. Williams. (2009) Radiation therapy of prostate cancer: rationale, pitfalls and the continuing prospect of success forged by medical physics. Australasian Physics & Engineering Sciences in Medicine 32:3, 119-128
CrossRef98
Francesco Montorsi, Richard Berges, Jacques Irani, Claude C. Schulman. (2009) Hormone Therapy for Prostate Cancer: Exploring Current Controversies. European Urology Supplements 8:9, 725-732
CrossRef99
Valérie Fonteyne, Geert Villeirs, Nicolaas Lumen, Gert De Meerleer. (2009) Urinary toxicity after high dose intensity modulated radiotherapy as primary therapy for prostate cancer. Radiotherapy and Oncology 92:1, 42-47
CrossRef100
Bolla, Michel, de Reijke, Theodorus M., Van Tienhoven, Geertjan, Van den Bergh, Alphonsus C.M., Oddens, Jorg, Poortmans, Philip M.P., Gez, Eliahu, Kil, Paul, Akdas, Atif, Soete, Guy, Kariakine, Oleg, van der Steen-Banasik, Elsbietha M., Musat, Elena, Piérart, Marianne, Mauer, Murielle E., Collette, Laurence, . (2009) Duration of Androgen Suppression in the Treatment of Prostate Cancer. New England Journal of Medicine 360:24, 2516-2527
Full Text101
Lockwood G. Taylor, Steven E. Canfield, Xianglin L. Du. (2009) Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 115:11, 2388-2399
CrossRef102
Philip J. Saylor, Matthew R. Smith. (2009) Metabolic Complications of Androgen Deprivation Therapy for Prostate Cancer. The Journal of Urology 181:5, 1998-2008
CrossRef103
Yi T. Koh, Andrew Gray, Sean A. Higgins, Bolyn Hubby, W. Martin Kast. (2009) Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization. The Prostate 69:6, 571-584
CrossRef104
Per Fransson, Jo-Åsmund Lund, Jan-Erik Damber, Olbjörn Klepp, Fredrik Wiklund, Sophie Fosså, Anders Widmark. (2009) Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial. The Lancet Oncology 10:4, 370-380
CrossRef105
Gustavo Arruda Viani, Antonio Cássio Pellizzon, Flavio Silva Guimarães, Alexandre Arthur Jacinto, Paulo Eduardo Ribeiro dos Santos Novaes, João Vitor Salvajoli. (2009) High Dose Rate and External Beam Radiotherapy in Locally Advanced Prostate Cancer. American Journal of Clinical Oncology 32:2, 187-190
CrossRef106
William D. Figg, Maha H. Hussain, James L. Gulley, Philip M. Arlen, Jeanny B. Aragon-Ching, Daniel P. Petrylak, Celestia S. Higano, Seth M. Steinberg, Gurkamal S. Chatta, Howard Parnes, John J. Wright, Oliver Sartor, William L. Dahut. (2009) A Double-Blind Randomized Crossover Study of Oral Thalidomide Versus Placebo for Androgen Dependent Prostate Cancer Treated With Intermittent Androgen Ablation. The Journal of Urology 181:3, 1104-1113
CrossRef107
Christian M. Zechmann, Khurram Aftab, Bernd Didinger, Frederik L. Giesel, Patrik Zamecnik, Christian Thieke, Jurgen J. Fütterer, Annette Kopp-Schneider, Hans-Ulrich Kauczor, Stefan Delorme. (2009) Changes of prostate gland volume with and without androgen deprivation after intensity modulated radiotherapy – A follow-up study. Radiotherapy and Oncology 90:3, 408-412
CrossRef108
Paul L. Nguyen, Ming-Hui Chen, William J. Catalona, Judd W. Moul, Leon Sun, Anthony V. D'Amico. (2009) Predicting Prostate Cancer Mortality Among Men With Intermediate to High-Risk Disease and Multiple Unfavorable Risk Factors. International Journal of Radiation Oncology*Biology*Physics 73:3, 659-664
CrossRef109
Seth A. Rosenthal, Kyoungwha Bae, Kenneth J. Pienta, Mark L. Sobczak, Sucha O. Asbell, Raghu Rajan, Kevin J. Kerlin, Jeff M. Michalski, Howard M. Sandler. (2009) Phase III Multi-Institutional Trial of Adjuvant Chemotherapy With Paclitaxel, Estramustine, and Oral Etoposide Combined With Long-Term Androgen Suppression Therapy and Radiotherapy Versus Long-Term Androgen Suppression Plus Radiotherapy Alone for High-Risk Prostate Cancer: Preliminary Toxicity Analysis of RTOG 99-02. International Journal of Radiation Oncology*Biology*Physics 73:3, 672-678
CrossRef110
M. E. Ray, K. Bae, M. H. A. Hussain, G. E. Hanks, W. U. Shipley, H. M. Sandler. (2009) Potential Surrogate Endpoints for Prostate Cancer Survival: Analysis of a Phase III Randomized Trial. JNCI Journal of the National Cancer Institute 101:4, 228-236
CrossRef111
Katia Ramos Moreira Leite, Luiz H.A. Camara-Lopes, Marcos F. Dall'Oglio, Jose Cury, Alberto A. Antunes, Adriana Sañudo, Miguel Srougi. (2009) Upgrading the Gleason Score in Extended Prostate Biopsy: Implications for Treatment Choice. International Journal of Radiation Oncology*Biology*Physics 73:2, 353-356
CrossRef112
Michael Pinkawa, Marc D. Piroth, Branka Asadpour, Bernd Gagel, Karin Fischedick, Jaroslav Siluschek, Mareike Kehl, Barbara Krenkel, Michael J. Eble. (2009) Neoadjuvant hormonal therapy and external-beam radiotherapy versus external-beam irradiation alone for prostate cancer. Strahlentherapie und Onkologie 185:2, 101-108
CrossRef113
Tatjana Josifovski, Cane Tulic, Aleksandar Milosevic, Ljiljana Radosevic-Jelic. (2009) Acute and late toxicity in radical radiotherapy of prostate cancer. Srpski arhiv za celokupno lekarstvo 137:1-2, 38-42
CrossRef114
Ljiljana Radosevic-Jelic, V. Stankovic, T. Josifovski, M. Dozic, N. Borojevic, C. Tulic. (2009) Combined hormono-radiotherapy in treatment of locally advanced prostate cancer. Acta chirurgica iugoslavica 56:4, 174-181
CrossRef115
Piotr Milecki, Maciej Baczyk, Janusz Skowronek, Andrzej Antczak, Zbigniew Kwias, Piotr Martenka. (2009) Benefit of Whole Pelvic Radiotherapy Combined with Neoadjuvant Androgen Deprivation for the High-Risk Prostate Cancer. Journal of Biomedicine and Biotechnology 2009, 1-9
CrossRef116
Martin Gleave, Laurence Klotz, Samir S. Taneja. (2009) The continued debate: Intermittent vs. continuous hormonal ablation for metastatic prostate cancer. Urologic Oncology: Seminars and Original Investigations 27:1, 81-86
CrossRef117
Shahrokh F. Shariat, Kai Hans Hammerich. (2009) Re: Timing of Androgen Deprivation Therapy and Its Impact on Survival after Radical Prostatectomy: A Matched Cohort Study. European Urology 55:1, 245-246
CrossRef118
Michael G. Oefelein. (2008) Androgen suppression therapy and prostate cancer. Cancer 113:12, 3275-3278
CrossRef119
William Kevin Kelly, Susan Halabi, Aymen Elfiky, San-San Ou, Jeff Bogart, Michael Zelefsky, Eric Small, . (2008) Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer. Cancer 113:11, 3137-3145
CrossRef120
Payam Hakimian, Michael Blute, James Kashanian, Sherman Chan, David Silver, Ridwan Shabsigh. (2008) Metabolic and cardiovascular effects of androgen deprivation therapy. BJU International 102:11, 1509-1514
CrossRef121
Makoto Sumitomo, Mutsuo Hayashi, Tetsuya Watanabe, Masaya Tsugawa, Hideya Noma, Akito Yamaguchi, Kazuhiko Nagakura, Masamichi Hayakawa, Toyoaki Uchida. (2008) Efficacy of Short-Term Androgen Deprivation With High-Intensity Focused Ultrasound in the Treatment of Prostate Cancer in Japan. Urology 72:6, 1335-1340
CrossRef122
Gert De Meerleer, Valérie Fonteyne, Sabine Meersschout, Caroline Van den Broecke, Geert Villeirs, Nicolaas Lumen, Piet Ost, Katrien Vandecasteele, Wilfried De Neve. (2008) Salvage intensity-modulated radiotherapy for rising PSA after radical prostatectomy. Radiotherapy and Oncology 89:2, 205-213
CrossRef123
Valérie Fonteyne, Geert Villeirs, Bruno Speleers, Wilfried De Neve, Carlos De Wagter, Nicolas Lumen, Gert De Meerleer. (2008) Intensity-Modulated Radiotherapy as Primary Therapy for Prostate Cancer: Report on Acute Toxicity After Dose Escalation With Simultaneous Integrated Boost to Intraprostatic Lesion. International Journal of Radiation Oncology*Biology*Physics 72:3, 799-807
CrossRef124
P. Richaud. (2008) Hormonothérapie adjuvante à la radiothérapie. Oncologie 10:11, 641-647
CrossRef125
Matthew D Katz, Gerald L Andriole. (2008) Are changes in US practices for androgen deprivation therapy financially motivated?. Nature Clinical Practice Urology 5:10, 534-535
CrossRef126
Hitoshi Ishikawa, Hiroshi Tsuji, Tadashi Kamada, Naoki Hirasawa, Takeshi Yanagi, Jun-Estu Mizoe, Koichiro Akakura, Hiroyoshi Suzuki, Jun Shimazaki, Takashi Nakano, Hirohiko Tsujii. (2008) Adverse Effects of Androgen Deprivation Therapy on Persistent Genitourinary Complications After Carbon Ion Radiotherapy for Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics 72:1, 78-84
CrossRef127
Fayez T. Hammad. (2008) Radical Prostatectomy. Annals of the New York Academy of Sciences 1138:1, 267-277
CrossRef128
Ludvig Paul Muren, Ellen Wasbø, Svein Inge Helle, Liv Bolstad Hysing, Àsa Karlsdottir, Odd Harald Odland, Harald Valen, Randi Ekerold, Dag Clement Johannessen. (2008) Intensity-Modulated Radiotherapy of Pelvic Lymph Nodes in Locally Advanced Prostate Cancer: Planning Procedures and Early Experiences. International Journal of Radiation Oncology*Biology*Physics 71:4, 1034-1041
CrossRef129
Sharon H. Giordano, Yong-Fang Kuo, Zhigang Duan, Gabriel N. Hortobagyi, Jean Freeman, James S. Goodwin. (2008) Limits of observational data in determining outcomes from cancer therapy. Cancer 112:11, 2456-2466
CrossRef130
Jan-Erik Damber, Gunnar Aus. (2008) Prostate cancer. The Lancet 371:9625, 1710-1721
CrossRef131
Simon M Collin, Richard M Martin, Chris Metcalfe, David Gunnell, Peter C Albertsen, David Neal, Freddie Hamdy, Peter Stephens, J Athene Lane, Rollo Moore, Jenny Donovan. (2008) Prostate-cancer mortality in the USA and UK in 1975–2004: an ecological study. The Lancet Oncology 9:5, 445-452
CrossRef132
Ása Karlsdóttir, Ludvig Paul Muren, Tore Wentzel-Larsen, Olav Dahl. (2008) Late Gastrointestinal Morbidity After Three-Dimensional Conformal Radiation Therapy for Prostate Cancer Fades With Time in Contrast to Genitourinary Morbidity. International Journal of Radiation Oncology*Biology*Physics 70:5, 1478-1486
CrossRef133
Nicolas Mottet, Jack A. Schalken, Axel Heidenreich, Patrick J. Bastian, Jacques Irani, Laurent Salomon, Michel Soulié. (2008) Highlights on Prostate Cancer from Urological and Oncological Congresses in 2007. European Urology Supplements 7:6, 460-476
CrossRef134
Steven Joniau, Hein Van Poppel. (2008) Localized prostate cancer: can we better define who is at risk of unfavourable outcome?. BJU International 101, 5-10
CrossRef135
S.H. Stübinger, R. Wilhelm, S. Kaufmann, M. Döring, S. Hautmann, K.P. Jünemann, R. Galalae. (2008) Brachytherapie des Prostatakarzinoms. Der Urologe 47:3, 284-290
CrossRef136
Judah Friedman, Rodney L. Dunn, David Wood, Ulka Vaishampayan, Angela Wu, Deborah Bradley, James Montie, Fazlul H. Sarkar, Rajal B. Shah, Maha Hussain. (2008) Neoadjuvant Docetaxel and Capecitabine in Patients With High Risk Prostate Cancer. The Journal of Urology 179:3, 911-916
CrossRef137
Sabina Hussain, David Gunnell, Jenny Donovan, Sean McPhail, Freddie Hamdy, David Neal, Peter Albertsen, Julia Verne, Peter Stephens, Caroline Trotter, Richard M. Martin. (2008) Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975–2004. BJU International 101:5, 547-555
CrossRef138
N Fleshner, T E Keane, C A Lawton, P F Mulders, H Payne, S S Taneja, T Morris. (2008) Adjuvant androgen deprivation therapy augments cure and long-term cancer control in men with poor prognosis, nonmetastatic prostate cancer. Prostate Cancer and Prostatic Diseases 11:1, 46-52
CrossRef139
Peter H GRAHAM, Zhi-Ming FANG, Raymond A CLARKE. (2008) Pre-treatment with anastrozole may be the optimal treatment sequence with radiotherapy for breast cancer. Asia-Pacific Journal of Clinical Oncology 4:1, 27-33
CrossRef140
Mohan Ramalingam, Weber Lau, Terence Tan, Stephanie Fook, Francis Ngoi, Christopher Cheng. (2008) Asians with Localized Prostate Cancer Treated with 3-Dimensional Conformal Radiation Therapy and Adjuvant Hormonal Therapy: Comparing Phoenix and American Society of Therapeutic Radiology and Oncology (ASTRO) Definitions in an Asian Population. Urology 71:3, 506-510
CrossRef141
Ulka Vaishampayan, Maha Hussain. (2008) Update in systemic therapy of prostate cancer: improvement in quality and duration of life. Expert Review of Anticancer Therapy 8:2, 269-281
CrossRef142
Kazuhiko Ogawa, Katsumasa Nakamura, Tomonari Sasaki, Hiroshi Onishi, Masahiko Koizumi, Masayuki Araya, Yoshiyuki Shioyama, Atsushi Okamoto, Michihide Mitsumori, Teruki Teshima, , . (2008) Radical external beam radiotherapy for prostate cancer in Japan: differences in the patterns of care among Japan, Germany, and the United States. Radiation Medicine 26:2, 57-62
CrossRef143
Piyush K. Agarwal, Natalia Sadetsky, Badrinath R. Konety, Martin I. Resnick, Peter R. Carroll, . (2008) Treatment failure after primary and salvage therapy for prostate cancer. Cancer 112:2, 307-314
CrossRef144
Sadao Kamidono, Shinichi Ohshima, Yoshihiko Hirao, Kazuhiro Suzuki, Yoichi Arai, Hiroyuki Fujimoto, Shin Egawa, Hideyuki Akaza, Isao Hara, Shiro Hinotsu, Yoshiyuki Kakehi, Tomonori Hasegawa. (2008) Evidence-based Clinical Practice Guidelines for Prostate Cancer (Summary - JUA 2006 Edition). International Journal of Urology 15:1, 1-18
CrossRef145
(2008) Editorial comment. BJU International 89:1, 17
CrossRef146
Michael Pinkawa, Karin Fischedick, Branka Asadpour, Bernd Gagel, Marc D. Piroth, Sandra Nussen, Michael J. Eble. (2008) Toxicity Profile With a Large Prostate Volume After External Beam Radiotherapy for Localized Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics 70:1, 83-89
CrossRef147
Axel Heidenreich, Gunnar Aus, Michel Bolla, Steven Joniau, Vsevolod B. Matveev, Hans Peter Schmid, Filliberto Zattoni. (2008) EAU Guidelines on Prostate Cancer. European Urology 53:1, 68-80
CrossRef148
Savita V. Dandapani, Martin G. Sanda. (2008) Measuring Health-Related Quality of Life Consequences From Primary Treatment for Early-Stage Prostate Cancer. Seminars in Radiation Oncology 18:1, 67-72
CrossRef149
Tatjana Josifovski, Ljiljana Radosevic-Jelic, Cane Tulic, Aleksandar Milosevic. (2008) Disease relapses after radical radiotherapy of prostate cancer: Analysis of prognostic factors. Srpski arhiv za celokupno lekarstvo 136:7-8, 373-378
CrossRef150
L Holmes, W Chan, Z Jiang, X L Du. (2007) Effectiveness of androgen deprivation therapy in prolonging survival of older men treated for locoregional prostate cancer. Prostate Cancer and Prostatic Diseases 10:4, 388-395
CrossRef151
C Lin, S Turner, T Mai, A Kneebone, V Gebski. (2007) Late rectal and urinary toxicity from conformal, dose-escalated radiation therapy for prostate cancer: A prospective study of 402 patients. Australasian Radiology 51:6, 578-583
CrossRef152
David K. Espey, Xiao-Cheng Wu, Judith Swan, Charles Wiggins, Melissa A. Jim, Elizabeth Ward, Phyllis A. Wingo, Holly L. Howe, Lynn A. G. Ries, Barry A. Miller, Ahmedin Jemal, Faruque Ahmed, Nathaniel Cobb, Judith S. Kaur, Brenda K. Edwards. (2007) Annual report to the nation on the status of cancer, 1975–2004, featuring cancer in American Indians and Alaska Natives. Cancer 110:10, 2119-2152
CrossRef153
Preston C Sprenkle, Harry Fisch. (2007) Pathologic effects of testosterone deprivation. Current Opinion in Urology 17:6, 424-430
CrossRef154
H. K. Tsai, A. V. D'Amico, N. Sadetsky, M.-H. Chen, P. R. Carroll. (2007) Androgen Deprivation Therapy for Localized Prostate Cancer and the Risk of Cardiovascular Mortality. JNCI Journal of the National Cancer Institute 99:20, 1516-1524
CrossRef155
Hiroshi Mayahara, Masao Murakami, Kazufumi Kagawa, Atsuya Kawaguchi, Yasue Oda, Daisuke Miyawaki, Ryohei Sasaki, Kazuro Sugimura, Yoshio Hishikawa. (2007) Acute Morbidity of Proton Therapy for Prostate Cancer: The Hyogo Ion Beam Medical Center Experience. International Journal of Radiation Oncology*Biology*Physics 69:2, 434-443
CrossRef156
Morgan Tharp, Richard Bennett, Jennifer Burns, W Terry Jones, David Scheidler, Philip Serbin, David Stuhldreher, Jeff Vaught, Yun Wang. (2007) Prostate High Dose Rate Brachytherapy in a Free-Standing Cancer Center Setting. American Journal of Clinical Oncology 30:5, 520-525
CrossRef157
C. Börgermann, K. Miller, F. Dorp, T. Jäger, H. Rübben. (2007) Gibt es eine Indikation für eine adjuvante oder neoadjuvante Systemtherapie beim Prostatakarzinom?. Der Urologe 46:10, 1385-1388
CrossRef158
Cristina Magi-Galluzzi, Ming Zhou, Alwyn M. Reuther, Robert Dreicer, Eric A. Klein. (2007) Neoadjuvant docetaxel treatment for locally advanced prostate cancer. Cancer 110:6, 1248-1254
CrossRef159
Charles J. Ryan, Tomasz M. Beer. (2007) Prostate Specific Antigen Only Androgen Independent Prostate Cancer: Natural History, Challenges in Management and Clinical Trial Design. The Journal of Urology 178:3, S25-S29
CrossRef160
D.P. Dearnaley. (2007) Radiotherapy and hormonal treatment. European Journal of Cancer Supplements 5:5, 177-188
CrossRef161
Paul L. Nguyen, Anthony L. Zietman. (2007) High-Dose External Beam Radiation for Localized Prostate Cancer: Current Status and Future Challenges. The Cancer Journal 13:5, 295-301
CrossRef162
Victor Valdespino, Panagiotis Tsagozis, Pavel Pisa. (2007) Current perspectives in the treatment of advanced prostate cancer. Medical Oncology 24:3, 273-286
CrossRef163
Fernand Labrie. (2007) Multiple intracrine hormonal targets in the prostate: opportunities and challenges. BJU International 100:s2 Prostate Can, 48-51
CrossRef164
Matthew R Smith. (2007) Androgen deprivation therapy for prostate cancer: new concepts and concerns. Current Opinion in Endocrinology, Diabetes and Obesity 14:3, 247-254
CrossRef165
Donald T.T. Yapp, Janet Woo, Aileen Kartono, Jonathan Sy, Thomas Oliver, Kirsten A. Skov, Cameron J. Koch, Hans Adomat, Wieslawa H. Dragowska, Ladan Fadzli, Thomas Ruth, Michael J. Adam, David Green, Martin Gleave. (2007) Non-invasive evaluation of tumour hypoxia in the Shionogi tumour model for prostate cancer with 18 F-EF5 and positron emission tomography. BJU International 99:5, 1154-1160
CrossRef166
Julie N. Graff, Motomi Mori, Hong Li, Mark Garzotto, David Penson, Arnold L. Potosky, Tomasz M. Beer. (2007) Predictors of Overall and Cancer-Free Survival of Patients With Localized Prostate Cancer Treated With Primary Androgen Suppression Therapy: Results From the Prostate Cancer Outcomes Study. The Journal of Urology 177:4, 1307-1312
CrossRef167
Paolo Gontero, Giansilvio Marchioro, Roberta Pisani, Stefano Zaramella, Filippo Sogni, Ervin Kocjancic, Nicola Mondaini, Daniele Bonvini, Alessandro Tizzani, Bruno Frea. (2007) Is Radical Prostatectomy Feasible in All Cases of Locally Advanced Non-Bone Metastatic Prostate Cancer? Results of a Single-Institution Study. European Urology 51:4, 922-930
CrossRef168
T. Jäger, A. Eisenhardt, H. Rübben, G. Lümmen. (2007) Beeinflusst Rauchen das Überleben von Prostatakarzinompatienten?. Der Urologe 46:4, 397-401
CrossRef169
Stephen J. Freedland, Alan W. Partin, Elizabeth B. Humphreys, Leslie A. Mangold, Patrick C. Walsh. (2007) Radical prostatectomy for clinical stage T3a disease. Cancer 109:7, 1273-1278
CrossRef170
Carys W. Thomas, Terry C. Bainbridge, Thomas A. Thomson, Colleen E. McGahan, W. James Morris. (2007) Clinical impact of second pathology opinion: A longitudinal study of central genitourinary pathology review before prostate brachytherapy. Brachytherapy 6:2, 135-141
CrossRef171
Paul H. Lange. (2007) Is Surgery Good for Advanced Localised Prostate Cancer? It's Time to Find Out!. European Urology 51:4, 873-875
CrossRef172
Manfred P. Wirth, Oliver W. Hakenberg, Michael Froehner. (2007) Optimal treatment of locally advanced prostate cancer. World Journal of Urology 25:2, 169-176
CrossRef173
Todd C. Tenenholz, Christian Shields, V. Ramakrishnan Ramesh, Oscar Tercilla, Michael P. Hagan. (2007) Survival benefit for early hormone ablation in biochemically recurrent prostate cancer. Urologic Oncology: Seminars and Original Investigations 25:2, 101-109
CrossRef174
Vinai Gondi, Israel Deutsch, Mahesh Mansukhani, Kathleen M. O’Toole, Jinesh N. Shah, Peter B. Schiff, Aaron E. Katz, Mitchell C. Benson, Erik T. Goluboff, Ronald D. Ennis. (2007) Intermediate-Risk Localized Prostate Cancer in the PSA Era: Radiotherapeutic Alternatives. Urology 69:3, 541-546
CrossRef175
Hazel Templeton. (2007) Prostate cancer ? presentation, diagnosis and treatment: what does the literature say?. International Journal of Urological Nursing 1:1, 6-17
CrossRef176
Stephanie C. Krejcarek, Ming-Hui Chen, Andrew A. Renshaw, Marian Loffredo, Brenda Sussman, Anthony V. D’Amico. (2007) Prediagnostic Prostate-Specific Antigen Velocity and Probability of Detecting High-Grade Prostate Cancer. Urology 69:3, 515-519
CrossRef177
Gert O. De Meerleer, Valérie H. Fonteyne, Luc Vakaet, Geert M. Villeirs, Ludwig Denoyette, Antony Verbaeys, Nicolas Lummen, Wilfried J. De Neve. (2007) Intensity-modulated radiation therapy for prostate cancer: Late morbidity and results on biochemical control. Radiotherapy and Oncology 82:2, 160-166
CrossRef178
Mark Pomerantz, Philip Kantoff. (2007) Advances in the Treatment of Prostate Cancer. Annual Review of Medicine 58:1, 205-220
CrossRef179
Chao-Yu Hsu, Steven Joniau, Raymond Oyen, Tania Roskams, Hein Van Poppel. (2007) Outcome of Surgery for Clinical Unilateral T3a Prostate Cancer: A Single-Institution Experience. European Urology 51:1, 121-129
CrossRef180
Steven B Zeliadt, David F Penson. (2007) Pharmacoeconomics of Available Treatment Options for Metastatic Prostate Cancer. PharmacoEconomics 25:4, 309-327
CrossRef181
Thinh P. Phan, A.M. Nisar Syed, Ajmel Puthawala, Anil Sharma, Farhan Khan. (2007) High Dose Rate Brachytherapy as a Boost for the Treatment of Localized Prostate Cancer. The Journal of Urology 177:1, 123-127
CrossRef182
Shabbir M.H. Alibhai, Sven Gogov, Zishan Allibhai. (2006) Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: A systematic literature review. Critical Reviews in Oncology/Hematology 60:3, 201-215
CrossRef183
Sandy Srinivas, Natalia Colocci. (2006) Bone Related Events in High Risk Prostate Cancer. The Journal of Urology 176:6, S50-S54
CrossRef184
P. Paula Hruska, Joel Picus. (2006) The role of primary chemotherapy for prostate cancer: Has the time come?. Current Prostate Reports 4:4, 157-162
CrossRef185
Oliver Sartor. (2006) Eligard® 6: A New Form of Treatment for Prostate Cancer. European Urology Supplements 5:18, 905-910
CrossRef186
Michihide Mitsumori, Yoshihide Sasaki, Takashi Mizowaki, Kenji Takayama, Yasushi Nagata, Masahiro Hiraoka, Yoshiharu Negoro, Keisuke Sasai, Hidefumi Kinoshita, Toshiyuki Kamoto, Osamu Ogawa. (2006) Results of radiation therapy combined with neoadjuvant hormonal therapy for stage III prostate cancer: comparison of two different definitions of PSA failure. International Journal of Clinical Oncology 11:5, 396-402
CrossRef187
Satish Kumar, Mike Shelley, Craig Harrison, Bernadette Coles, Timothy J. Wilt, Malcolm Mason, Mike Shelley. 2006. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. .
CrossRef188
Alberto Briganti, Felix K-H. Chun, Andrea Salonia, Andrea Gallina, Elena Farina, Luigi F. Da Pozzo, Patrizio Rigatti, Francesco Montorsi, Pierre I. Karakiewicz. (2006) Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer. BJU International 98:4, 788-793
CrossRef189
Jeremy Ockrim, El-Nasir Lalani, Paul Abel. (2006) Therapy Insight: parenteral estrogen treatment for prostate cancer—a new dawn for an old therapy. Nature Clinical Practice Oncology 3:10, 552-563
CrossRef190
Danish Mazhar, Sarah Ngan, Jonathan Waxman. (2006) Improving outcomes in early prostate cancer: Part I ? adjuvant treatment. BJU International 98:4, 725-730
CrossRef191
Seok-Ho Kang, Jin-Wook Kim, Jae-Hyun Bae, Hong-Seok Park, Du-Geon Moon, Duck-Ki Yoon, Jun Cheon, Je-Jong Kim. (2006) Targeted-cryosurgical ablation of the prostate with androgen deprivation therapy: quality of life in high-risk prostate cancer patients. Asian Journal of Andrology 8:5, 629-636
CrossRef192
S.J. Khaksar, S.E.M. Langley, D. Lovell, R.W. Laing. (2006) Interstitial Low Dose Rate Brachytherapy for Prostate Cancer — A Focus on Intermediate- and High-risk Disease. Clinical Oncology 18:7, 513-518
CrossRef193
Toshihiro Saito, Yasuo Kitamura, Shuichi Komatsubara, Yasuo Matsumoto, Tadashi Sugita, Noboru Hara. (2006) Outcomes of locally advanced prostate cancer: a single institution study of 209 patients in Japan. Asian Journal of Andrology 8:5, 555-561
CrossRef194
Brett S. Carver, Fernando J. Bianco, Peter T. Scardino, James A. Eastham. (2006) Long-Term Outcome Following Radical Prostatectomy in Men With Clinical Stage T3 Prostate Cancer. The Journal of Urology 176:2, 564-568
CrossRef195
Neesha A. Rodrigues, Ming-Hui Chen, William J. Catalona, Kimberly A. Roehl, Jerome P. Richie, Anthony V. D'Amico. (2006) Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer. Cancer 107:3, 514-520
CrossRef196
Andrew K. Lee, Steven J. Frank. (2006) Update on Radiation Therapy in Prostate Cancer. Hematology/Oncology Clinics of North America 20:4, 857-878
CrossRef197
Mark D. Hurwitz, Delray Schultz, Jerome P. Richie, Alan J. Wein, Richard Whittington, S. Bruce Malkowicz, Anthony V. D’Amico. (2006) Radical prostatectomy for high-grade prostate cancer. Urology 68:2, 367-370
CrossRef198
Tracey L. Krupski, Christopher S. Saigal, Janet Hanley, Matthias Schonlau, Mark S. Litwin, . (2006) Patterns of care for men with prostate cancer after failure of primary treatment. Cancer 107:2, 258-265
CrossRef199
P. F. Schellhammer. (2006) Timing of Androgen Deprivation Therapy: Some Questions Answered, Others Not. JNCI Journal of the National Cancer Institute 98:12, 802-803
CrossRef200
V. B. Shahinian, Y.-F. Kuo, J. L. Freeman, J. S. Goodwin. (2006) Determinants of Androgen Deprivation Therapy Use for Prostate Cancer: Role of the Urologist. JNCI Journal of the National Cancer Institute 98:12, 839-845
CrossRef201
Ryan K. Berglund, J. Stephen Jones, James C. Ulchaker, Amr Fergany, Inderbir Gill, Jihad Kaouk, Eric A. Klein. (2006) Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: A prospective analysis. Urology 67:6, 1253-1256
CrossRef202
P. Paula Hruska, Joel Picus. (2006) The role of primary chemotherapy for prostate cancer: Has the time come?. Current Urology Reports 7:3, 233-238
CrossRef203
Philippe E. Spiess, Dan Leibovici, Louis L. Pisters. (2006) Surgery for locally advanced disease. Current Prostate Reports 4:2, 59-66
CrossRef204
Christopher R. King, John E. McNeal, Harcharan Gill, James D. Brooks, Sandy Srinivas, Joseph C. Presti. (2006) Reliability of small amounts of cancer in prostate biopsies to reveal pathologic grade. Urology 67:6, 1229-1234
CrossRef205
Philippe E. Spiess, Dan Leibovici, Louis L. Pisters. (2006) Surgery for locally advanced disease. Current Urology Reports 7:3, 209-216
CrossRef206
Jyoti Shah, Sara Jane Khaksar, Prasanna Sooriakumaran. (2006) Management of prostate cancer. Part 3: metastatic disease. Expert Review of Anticancer Therapy 6:5, 813-821
CrossRef207
COLIN C.W. CHONG, LYNETTE AUSTEN, ANDREW KNEEBONE, ANDRE LALAK, BIN JALALUDIN. (2006) Patterns of practice in the management of prostate cancer: results from multidisciplinary surveys of clinicians in Australia and New Zealand in 1995 and 2000. BJU International 97:5, 975-980
CrossRef208
Jonathan L. Wright, Celestia S. Higano, Daniel W. Lin. (2006) Intermittent Androgen Deprivation: Clinical Experience and Practical Applications. Urologic Clinics of North America 33:2, 167-179
CrossRef209
Gang Wang, Marianne D. Sadar. (2006) Amino-terminus domain of the androgen receptor as a molecular target to prevent the hormonal progression of prostate cancer. Journal of Cellular Biochemistry 98:1, 36-53
CrossRef210
Jeffrey M. Holzbeierlein. (2006) Managing Complications of Androgen Deprivation Therapy for Prostate Cancer. Urologic Clinics of North America 33:2, 181-190
CrossRef211
Ganesh S Palapattu, Edward M Messing. (2006) Do prostate cancer patients at risk of pelvic lymph-node metastasis benefit from pelvic radiation?. Nature Clinical Practice Urology 3:5, 258-259
CrossRef212
Mark Garzotto, Anne Myrthue, Celestia S. Higano, Tomasz M. Beer. (2006) Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer. Urologic Oncology: Seminars and Original Investigations 24:3, 254-259
CrossRef213
Hideyuki Akaza. (2006) Trends in primary androgen depletion therapy for patients with localized and locally advanced prostate cancer: Japanese perspective. Cancer Science 97:4, 243-247
CrossRef214
Pauline Gastelblum, Martine Roelandts, Paul Van Houtte. (2006) External Radiotherapy and Prostate Cancer. European Urology Supplements 5:6, 487-490
CrossRef215
F. Yoon, G. Rodrigues, D. D'Souza, J. Radwan, M. Lock, G. Bauman, R. Ash, V. Venketesan, D. Downey, L. Stitt, D. Weisz, J. Izawa. (2006) Assessing the Prognostic Significance of Transrectal Ultrasound Extracapsular Extension in Prostate Cancer. Clinical Oncology 18:2, 117-124
CrossRef216
Haruki Kaku, Takashi Saika, Tomoyasu Tsushima, Shin Ebara, Takashi Senoh, Toyoko Yamato, Yasutomo Nasu, Hiromi Kumon. (2006) Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. The Prostate 66:4, 439-444
CrossRef217
Shehzad Basaria, Denis C. Muller, Michael A. Carducci, Josephine Egan, Adrian S. Dobs. (2006) Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 106:3, 581-588
CrossRef218
Fabio Levi, Franca Lucchini, Carlo La Vecchia. (2006) Trends in cancer mortality in Switzerland, 1980???2001. European Journal of Cancer Prevention 15:1, 1-9
CrossRef219
Olav Erich Yri, Trine Bjoro, Sophie D. Fossa. (2006) Failure to Achieve Castration Levels in Patients Using Leuprolide Acetate in Locally Advanced Prostate Cancer. European Urology 49:1, 54-58
CrossRef220
Matthew R. Smith, Simone Peart Boyce, Erick Moyneur, Mei Sheng Duh, Monika K. Raut, Jane Brandman. (2006) Risk of Clinical Fractures After Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer. The Journal of Urology 175:1, 136-139
CrossRef221
Ryoong-Jin Oh, Yasuo Yoshioka, Eiichi Tanaka, Hiroya Shiomi, Iori Sumida, Fumiaki Isohashi, Osamu Suzuki, Koji Konishi, Yoshifumi Kawaguchi, Satoaki Nakamura, Masahiro Kato, Takehiro Inoue. (2006) High-dose-rate brachytherapy combined with long-term hormonal therapy for high-risk prostate cancer: Results of a retrospective analysis. Radiation Medicine 24:1, 58-64
CrossRef222
Andre Konski, Deborah Watkins-Bruner, Harmar Brereton, Steven Feigenberg, Gerald Hanks. (2006) Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma. Cancer 106:1, 51-57
CrossRef223
Emina Torlakovic, Wolfgang Lilleby, Aasmund Berner, Goran Torlakovic, Rajni Chibbar, Torbjørn Furre, Sophie D. Fosså. (2005) Differential expression of steroid receptors in prostate tissues before and after radiation therapy for prostatic adenocarcinoma. International Journal of Cancer 117:3, 381-386
CrossRef224
M. P. Wirth, O. W. Hakenberg, M. Fröhner. (2005) Therapie des lokal fortgeschrittenen Prostatakarzinoms. Der Urologe 44:11, 1295-1302
CrossRef225
Roger S. Kirby, John M. Fitzpatrick. (2005) Radical prostatectomy vs watchful waiting. BJU International 96:7, 953-954
CrossRef226
Laurence Klotz. (2005) Optimising Hormone Therapy in Localised and Early Disease. European Urology Supplements 4:8, 12-20
CrossRef227
Gary R. MacVicar, Maha Hussain. (2005) Chemotherapy for prostate cancer: implementing early systemic therapy to improve outcomes. Cancer Chemotherapy and Pharmacology 56:S1, 69-77
CrossRef228
SANGTAE PARK, MAXWELL V. MENG, ERIC P. ELKIN, JOYCELYN L. SPEIGHT, JANEEN DuCHANE, PETER R. CARROLL. (2005) ANDROGEN DEPRIVATION USE WITH EXTERNAL BEAM RADIATION FOR PROSTATE CANCER: RESULTS FROM CaPSURE™. The Journal of Urology 174:5, 1802-1807
CrossRef229
Martin Gleave, Hideaki Miyake, Kim Chi. (2005) Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer. Cancer Chemotherapy and Pharmacology 56:S1, 47-57
CrossRef230
Alan M. Nichol, Padraig Warde, Robert G. Bristow. (2005) Optimal treatment of intermediate-risk prostate carcinoma with radiotherapy. Cancer 104:5, 891-905
CrossRef231
Juan Morote, Salvador Esquena, Anna Orsola, Carlos Salvador, Enrique Trilla, Luis Cecchini, Carles X. Ravent??s, Jacques Planas, Roberto Catal??n, Jaume Revent??s. (2005) Effect of androgen deprivation therapy in the thyroid function test of patients with prostate cancer. Anti-Cancer Drugs 16:8, 863-866
CrossRef232
Christine A. Stone, Frank W. May, Carole B. Pinnock, Mark Elwood, Debra S. Rowett. (2005) Prostate cancer, the PSA test and academic detailing in Australian general practice: an economic evaluation. Australian and New Zealand Journal of Public Health 29:4, 349-357
CrossRef233
DAVID C. MILLER, JAMES E. MONTIE, JOHN T. WEI. (2005) MEASURING THE QUALITY OF CARE FOR LOCALIZED PROSTATE CANCER. The Journal of Urology 174:2, 425-431
CrossRef234
David F. Penson. (2005) An update on randomized clinical trials in localized and locoregional prostate cancer. Urologic Oncology: Seminars and Original Investigations 23:4, 280-288
CrossRef235
Henry K. Tsai, Judith Manola, Anthony Abner, James A. Talcott, Anthony V. D’Amico, Clair Beard. (2005) Patient-reported acute gastrointestinal toxicity in men receiving 3-dimensional conformal radiation therapy for prostate cancer with or without neoadjuvant androgen suppression therapy. Urologic Oncology: Seminars and Original Investigations 23:4, 230-237
CrossRef236
P. Mongiat-Artus, P. Teillac. (2005) Role of Luteinising Hormone Releasing Hormone (LHRH) Agonists and Hormonal Treatment in the Management of Prostate Cancer. European Urology Supplements 4:5, 4-13
CrossRef237
U. Ganswindt, F. Paulsen, A. G. Anastasiadis, A. Stenzl, M. Bamberg, C. Belka. (2005) 70 Gy or more: which dose for which prostate cancer?. Journal of Cancer Research and Clinical Oncology 131:7, 407-419
CrossRef238
Ramesh Thurairaja, Rajendra Persad, John Peters, Amit Bahl. (2005) The 'flare' phenomenon: should we be concerned?. BJU International 96:1, 4-6
CrossRef239
Nicole Miller, Mark E. Smolkin, Eric Bissonette, Dan Theodorescu. (2005) Undetectable prostate specific antigen at 6-12 months. Cancer 103:12, 2499-2506
CrossRef240
Tony Y. Eng, Join Y. Luh, Charles R. Thomas. (2005) The efficacy of conventional external beam, three-dimensional conformal, intensity-modulated, particle beam radiation, and brachytherapy for localized prostate cancer. Current Urology Reports 6:3, 194-209
CrossRef241
M Kasibhatla, B Peterson, M S Anscher. (2005) What is the best postoperative treatment for patients with pT3bN0M0 adenocarcinoma of the prostate?. Prostate Cancer and Prostatic Diseases 8:2, 167-173
CrossRef242
Hillary Copp, Eric A. Bissonette, Dan Theodorescu. (2005) Tumor control outcomes of patients treated with trimodality therapy for locally advanced prostate cancer. Urology 65:6, 1146-1151
CrossRef243
Paul L. Nguyen, Richard Whittington, Sophia Koo, Delray Schultz, Kerri B. Cote, Marian Loffredo, Elizabeth McMahon, Andrew A. Renshaw, John E. Tomaszewski, Anthony V. D'Amico. (2005) The impact of a delay in initiating radiation therapy on prostate-specific antigen outcome for patients with clinically localized prostate carcinoma. Cancer 103:10, 2053-2059
CrossRef244
Kathleen Beekman, Michael Morris, Susan Slovin, Glenn Heller, Andrew Wilton, Fernando Bianco, Peter T. Scardino, Howard I. Scher. (2005) Androgen deprivation for minimal metastatic disease: Threshold for achieving undetectable prostate-specific antigen. Urology 65:5, 947-952
CrossRef245
Athanasios Colonias, Lloyd Farinash, Linda Miller, Sandra Jones, David S Medich, Larisa Greenberg, Ralph Miller, David S Parda. (2005) Multidisciplinary treatment of synchronous primary rectal and prostate cancers. Nature Clinical Practice Oncology 2:5, 271-274
CrossRef246
Vahakn B. Shahinian, Yong-fang Kuo, Jean L. Freeman, Eduardo Orihuela, James S. Goodwin. (2005) Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 103:8, 1615-1624
CrossRef247
Hidetoshi Yamanaka, Kazuto Ito, Seiji Naito, Taiji Tsukamoto, Michiyuki Usami, Hiroyuki Fujimoto, Naoki Matsuoka, Iwao Fukui, Masaoki Harada, Yasuo Ohashi, Toshihiko Kotake, Tadao Kakizoe. (2005) Effectiveness of adjuvant intermittent endocrine therapy following neoadjuvant endocrine therapy and external beam radiation therapy in men with locally advanced prostate cancer. The Prostate 63:1, 56-64
CrossRef248
Serdar Deger, Dirk Boehmer, Jan Roigas, Tania Schink, Klaus Dieter Wernecke, Thomas Wiegel, Wolfgang Hinkelbein, Volker Budach, Stefan A. Loening. (2005) High Dose Rate (HDR) Brachytherapy with Conformal Radiation Therapy for Localized Prostate Cancer. European Urology 47:4, 441-448
CrossRef249
Anthony L Zietman. (2005) Do patients with low-risk and intermediate-risk prostate cancer benefit from androgen deprivation?. Nature Clinical Practice Urology 2:4, 160-161
CrossRef250
S. Ladoire, F. Ghiringhelli, P. Manckoundia, R.O. Casasnovas, E. Solary, J.F. Besancenot, P. Pfitzenmeyer. (2005) Prise en charge des cancers solides et des hémopathies malignes du sujet âgé : l'oncogériatrie, une discipline en devenir. Seconde partie : traitement des cancers solides (partie 2) et des hémopathies malignes du sujet âgé. La Revue de Médecine Interne 26:4, 304-314
CrossRef251
Peter Whelan. (2005) Hormone Therapy in Prostate Cancer: Moving into the 21st Century. European Urology Supplements 4:4, 53-56
CrossRef252
Takahiko Hachiya, Koichiro Akakura, Shiro Saito, Nobuo Shinohara, Kazunari Sato, Masaoki Harada, Tetsuro Kato, Kiyoki Okada. (2005) A retrospective study of the treatment of locally advanced prostate cancer by six institutions in eastern and north-eastern Japan. BJU International 95:4, 534-540
CrossRef253
Lisa B. Bland, Mark Garzotto, Thomas G. DeLoughery, Christopher W. Ryan, Kathryn G. Schuff, Emily M. Wersinger, Dianne Lemmon, Tomasz M. Beer. (2005) Phase II study of transdermal estradiol in androgen-independent prostate carcinoma. Cancer 103:4, 717-723
CrossRef254
Jan-Erik Damber. (2005) Endocrine therapy for prostate cancer. Acta Oncologica 44:6, 605-609
CrossRef255
Mark D. Hurwitz, Irving D. Kaplan, Jorgen L. Hansen, Savina Prokopios-Davos, George P. Topulos, Kenneth Wishnow, Judith Manola, Bruce A. Bornstein, Kullervo Hynynen. (2005) Hyperthermia combined with radiation in treatment of locally advanced prostate cancer is associated with a favourable toxicity profile. International Journal of Hyperthermia 21:7, 649-656
CrossRef256
Thomas Wahlgren, Sten Nilsson, Marianne Ryberg, Bo Lennernäs, Yvonne Brandberg. (2005) Combined curative radiotherapy including HDR brachytherapy and androgen deprivation in localized prostate cancer: A prospective assessment of acute and late treatment toxicity. Acta Oncologica 44:6, 633-643
CrossRef257
Mark A. Moyad. (2005) Promoting general health during androgen deprivation therapy (ADT): A rapid 10-step review for your patients. Urologic Oncology: Seminars and Original Investigations 23:1, 56-64
CrossRef258
Joseph R. Bussiere, Tomasz M. Beer, Michelle B. Neiss, Jeri S. Janowsky. (2005) Androgen Deprivation Impairs Memory in Older Men.. Behavioral Neuroscience 119:6, 1429-1437
CrossRef259
H. Matzkin, G. Keren-Paz, N.J. Mabjeesh, J. Chen. (2005) Combination therapy-permanent interstitial brachytherapy and external beam radiotherapy for patients with localized prostate cancer. Acta chirurgica iugoslavica 52:4, 31-36
CrossRef260
J OCKRIM, E LALANI, L BANKS, W SVENSSON, M BLOMLEY, S PATEL, M LANIADO, S CARTER, P ABEL. (2004) TRANSDERMAL ESTRADIOL IMPROVES BONE DENSITY WHEN USED AS SINGLE AGENT THERAPY FOR PROSTATE CANCER. The Journal of Urology 172:6, 2203-2207
CrossRef261
Fernand Labrie, Leonello Cusan, José Gomez, Van Luu-The, Bernard Candas, Alain Bélanger, Claude Labrie. (2004) Major impact of hormonal therapy in localized prostate cancer—death can already be an exception. The Journal of Steroid Biochemistry and Molecular Biology 92:5, 327-344
CrossRef262
Steven B. Zeliadt, Arnold L. Potosky, Ruth Etzioni, Scott D. Ramsey, David F. Penson. (2004) Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology 64:6, 1171-1176
CrossRef263
Gregory S. Merrick, Wayne M. Butler, Kent E. Wallner, Robert W. Galbreath, Edward Adamovich. (2004) Permanent Interstitial Brachytherapy for Clinically Organ-Confined High-Grade Prostate Cancer With a Pretreatment PSA < 20 ng/mL. American Journal of Clinical Oncology 27:6, 611-615
CrossRef264
S. Packianathan, Rajendra G. Mehta, Rajeshwari R. Mehta, William H. Hall, Philip S. Boerner, Laurel A. Beckett, Srinivasan Vijayakumar. (2004) Designing a Randomized Phase I/II Prostate Cancer Chemoprevention Trial Using 1??-Hydroxy-24-Ethyl-Cholecalciferol, an Analogue of Vitamin D3. The Cancer Journal 10:6, 357-367
CrossRef265
Teuvo Tammela. (2004) Endocrine treatment of prostate cancer. The Journal of Steroid Biochemistry and Molecular Biology 92:4, 287-295
CrossRef266
Clarissa Febles, Richard K. Valicenti. (2004) Combining external beam radiotherapy with prostate brachytherapy: Issues and rationale. Urology 64:5, 855-861
CrossRef267
Kirsten Skov, Hans Adomat, Mary Bowden, Wieslawa Dragowska, Martin Gleave, Cameron J. Koch, Janet Woo, Donald T. T. Yapp. (2004) Hypoxia in the Androgen-Dependent Shionogi Model for Prostate Cancer at Three Stages 1. Radiation Research 162:5, 547-553
CrossRef268
Brent K. Hollenbeck, Rodney L. Dunn, John T. Wei, Howard M. Sandler, Martin G. Sanda. (2004) Sexual health recovery after prostatectomy, external radiation, or brachytherapy for early-stage prostate cancer. Current Prostate Reports 2:3, 109-116
CrossRef269
Dawn Hershman, Rashmi Narayanan. (2004) Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer. Current Oncology Reports 6:4, 277-284
CrossRef270
Shawn Malone. (2004) Dose-escalated 3D conformal radiotherapy in prostate cancer. Expert Review of Anticancer Therapy 4:4, 663-668
CrossRef271
Rama S. Ranga, Ramankutty Girija, Mohammed Nur-e-alam, Sabapathy Sathishkumar, Mohammed A. Akbarsha, Subbiah Thirugnanam, J
CrossRef272
Fabio Levi, Franca Lucchini, Eva Negri, Peter Boyle, Carlo La Vecchia. (2004) Leveling of prostate cancer mortality in Western Europe. The Prostate 60:1, 46-52
CrossRef273
Fabio Levi, Franca Lucchini, Eva Negri, Peter Boyle, Carlo La Vecchia. (2004) Cancer mortality in Europe, 1995-1999, and an overview of trends since 1960. International Journal of Cancer 110:2, 155-169
CrossRef274
HIDEAKI MIYAKE, IORI SAKAI, KEN-ICHI HARADA, ISAO HARA, HIROSHI ETO. (2004) Long-term results of adjuvant hormonal therapy plus radiotherapy following radical prostatectomy for patients with pT3N0 or pT3N1 prostate cancer. International Journal of Urology 11:6, 397-401
CrossRef275
Hiroshi Miyamoto, Edward M. Messing. (2004) Early versus late hormonal therapy for prostate cancer. Current Prostate Reports 2:2, 60-68
CrossRef276
Fernand Labrie, Bernard Candas, Lionel Cusan, Jose Luis Gomez, Alain B
CrossRef277
Brent K. Hollenbeck, Rodney L. Dunn, John T. Wei, Howard M. Sandler, Martin G. Sanda. (2004) Sexual health recovery after prostatectomy, external radiation, or brachytherapy for early stage prostate cancer. Current Urology Reports 5:3, 212-219
CrossRef278
Jeffrey M Holzbeierlein, Matthew D McLaughlin, J Brantley Thrasher. (2004) Complications of androgen deprivation therapy for prostate cancer. Current Opinion in Urology 14:3, 177-183
CrossRef279
Richard E. Peschel, John W. Colberg, Zhe Chen, Ravinder Nath, Lynn D. Wilson. (2004) Iodine 125 Versus Palladium 103 Implants for Prostate Cancer. The Cancer Journal 10:3, 170-174
CrossRef280
Matthew R. Cooperberg, Jeanette M. Broering, David M. Latini, Mark S. Litwin, Katrine L. Wallace, Peter R. Carroll. (2004) Patterns of practice in the United States: Insights from CaPSURE on prostate cancer management. Current Urology Reports 5:3, 166-172
CrossRef281
Hiroshi Miyamoto, Edward M. Messing. (2004) Early versus late hormonal therapy for prostate cancer. Current Urology Reports 5:3, 188-196
CrossRef282
A.I. So, M. Bowden, M. Gleave. (2004) Effect of time of castration and tumour volume on time to androgen-independent recurrence in Shionogi tumours. BJU International 93:6, 845-850
CrossRef283
L. Boccon-Gibod, B. Djavan, P. Hammerer, W. Hoeltl, M.W. Kattan, T. Prayer-Galetti, P. Teillac, U.W. Tunn. (2004) Management of prostate-specific antigen relapse in prostate cancer: A European consensus. International Journal of Clinical Practice 58:4, 382-390
CrossRef284
A.M. Henry, P. Price, J.P. Logue, R.A. Cowan, J.H. Shanks, D.P. Dearnaley, V.S. Khoo. (2004) Controversies in the Radiotherapeutic Management of Poor Prognosis Locally Advanced Prostate Cancer. Clinical Oncology 16:2, 87-94
CrossRef285
J.-E. Damber. (2004) Decreasing mortality rates for prostate cancer: possible role of hormonal therapy?. BJU International 93:6, 695-701
CrossRef286
Matthew R. Cooperberg, Jeanette M. Broering, David M. Latini, Mark S. Litwin, Katrine L. Wallace, Peter R. Carroll. (2004) Patterns of practice in the United States: Insights from CaPSURE on prostate cancer management. Current Prostate Reports 2:1, 5-11
CrossRef287
PO HUI CHIANG, FU MIN FANG, WANG CHONG JONG, TSAN JUNG YU, YAO CHI CHUANG, HUNG JEN WANG. (2004) High-dose rate iridium-192 brachytherapy and external beam radiation therapy for prostate cancer with or without androgen ablation. International Journal of Urology 11:3, 152-158
CrossRef288
Terrence H. Diamond, Celestia S. Higano, Matthew R. Smith, Theresa A. Guise, Frederick R. Singer. (2004) Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy. Cancer 100:5, 892-899
CrossRef289
JACQUES LAVERDIÈRE, ABDENOUR NABID, LUIS DIAZ DE BEDOYA, ANNIE ÉBACHER, ANDRÉ FORTIN, CHANG SHU WANG, FRANÇOIS HAREL. (2004) The Efficacy and Sequencing of a Short Course of Androgen Suppression on Freedom From Biochemical Failure When Administered With Radiation Therapy for T2-T3 Prostate Cancer. The Journal of Urology 171:3, 1137-1140
CrossRef290
Samuel R. Denmeade, John T. Isaacs. (2004) Development of prostate cancer treatment: The good news. The Prostate 58:3, 211-224
CrossRef291
T.J. FitzGerald, Edmund Simon, Joshua Meyer. (2004) Prostate carcinoma: Opportunities for translational research. Journal of Cellular Biochemistry 91:3, 433-442
CrossRef292
Rena G. Lapidus, Wenbin Dang, David Marc Rosen, Alyssa M. Gady, Yelena Zabelinka, Robert O'Meally, Theodore L. DeWeese, Samuel R. Denmeade. (2004) Anti-tumor effect of combination therapy with intratumoral controlled-release paclitaxel (PACLIMER
CrossRef293
Mary-Ellen Taplin, Steven P. Balk. (2004) Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence. Journal of Cellular Biochemistry 91:3, 483-190
CrossRef294
Aldo V Bono. (2004) Overview of Current Treatment Strategies in Prostate Cancer. European Urology Supplements 3:1, 2-7
CrossRef295
Brace L. Hintz, Charles Koo, James F. Murphy. (2004) Pattern of Proliferative Index (Ki-67) After Anti-Androgen Manipulation Reflects the Ability of Irradiation to Control Prostate Cancer. American Journal of Clinical Oncology 27:1, 85-88
CrossRef296
Jesus Benjamin Mendoza. (2004) The Role of Hormonal Therapy in the Treatment of Locally Advanced Prostate Cancer—Regional Perspectives: Asia. European Urology Supplements 3:1, 12-16
CrossRef297
E.David Crawford. (2004) The Role of Hormonal Therapy in the Treatment of Locally Advanced Prostate Cancer—Regional Perspectives: USA. European Urology Supplements 3:1, 17-21
CrossRef298
M. van Vulpen, A.A.C. de Leeuw, B.W. Raaymakers, R.J.A. van Moorselaar, P. Hofman, J.J.W. Lagendijk, J.J. Battermann. (2004) Radiotherapy and hyperthermia in the treatment of patients with locally advanced prostate cancer: preliminary results. BJU International 93:1, 36-41
CrossRef299
Moon Kee Chung. (2004) Review of the Treatment Outcome in the Adenocarcinoma of the Prostate. Journal of the Korean Medical Association 47:5, 432
CrossRef300
James A Eastham. (2004) Multimodal treatment strategies combining neoadjuvant hormonal therapy and/or chemotherapy with radical prostatectomy in high-risk localised prostate cancer. Expert Opinion on Investigational Drugs 13:1, 39-46
CrossRef301
H. Akaza. (2004) Adjuvant goserelin improves clinical disease-free survival and reduces disease-related mortality in patients with locally advanced or localized prostate cancer. BJU International 93:1, 42-46
CrossRef302
Andrew Kneebone, Sandra Turner, Martin Berry, Burcu Cakir, Val Gebski. (2003) Australian prostate-specific antigen outcome and toxicity following radiation therapy for localized prostate cancer. Australasian Radiology 47:4, 422-427
CrossRef303
James A Eastham, William K Kelly, Gary D Grossfeld, Eric J Small. (2003) Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology 62, 55-62
CrossRef304
James Gulley, William L Dahut. (2003) Novel approaches to treating the asymptomatic hormone-refractory prostate cancer patient. Urology 62, 147-154
CrossRef305
Christopher J Diblasio, Michael W Kattan. (2003) Use of nomograms to predict the risk of disease recurrence after definitive local therapy for prostate cancer. Urology 62, 9-18
CrossRef306
ALVARO MARTINEZ, RAZVAN GALALAE, JOSE GONZALEZ, CHRISTINA MITCHELL, GARY GUSTAFSON, GYORGY KOVACS. (2003) No Apparent Benefit at 5 Years From a Course of Neoadjuvant/Concurrent Androgen Deprivation for Patients With Prostate Cancer Treated With a High Total Radiation Dose. The Journal of Urology 170:6, 2296-2301
CrossRef307
CELESTIA S. HIGANO. (2003) Management of Bone Loss in Men With Prostate Cancer. The Journal of Urology 170:6, S59-S64
CrossRef308
Malcolm Mason. (2003) How Should We Treat Patients with Locally Advanced Prostate Cancer?. European Urology Supplements 2:9, 14-22
CrossRef309
Bert T Chen, David P Wood. (2003) Salvage prostatectomy in patients who have failed radiation therapy or cryotherapy as primary treatment for prostate cancer. Urology 62, 69-78
CrossRef310
Judd W Moul, Jackson E Fowler. (2003) Evolution of therapeutic approaches with luteinizing hormone–releasing hormone agonists in 2003. Urology 62:6, 20-28
CrossRef311
Bin S. Teh, Michael D. Bastasch, Wei-Yuan Mai, E. Brian Butler, Thomas M. Wheeler. (2003) Predictors of Extracapsular Extension and Its Radial Distance in Prostate Cancer. The Cancer Journal 9:6, 454-460
CrossRef312
DOUGLAS S. SCHERR, W. REID PITTS. (2003) The Nonsteroidal Effects of Diethylstilbestrol: The Rationale for Androgen Deprivation Therapy Without Estrogen Deprivation in the Treatment of Prostate Cancer. The Journal of Urology 170:5, 1703-1708
CrossRef313
James A Eastham. (2003) High-risk localised prostate cancer: multimodal treatment strategies combining neoadjuvant hormonal therapy and/or chemotherapy with radical prostatectomy. Expert Opinion on Emerging Drugs 8:2, 291-295
CrossRef314
Charles Catton, Michael Milosevic, Padraig Warde, Andrew Bayley, Juanita Crook, Robert Bristow, Mary Gospodarowicz. (2003) Recurrent prostate cancer following external beam radiotherapy. Urologic Clinics of North America 30:4, 751-763
CrossRef315
Harrie P. Beerlage. (2003) Alternative therapies for localized prostate cancer. Current Prostate Reports 1:2, 66-70
CrossRef316
William A. See. (2003) Adjuvant hormone therapy after radiation or surgery for localized or locally advanced prostate cancer. Current Treatment Options in Oncology 4:5, 351-362
CrossRef317
Christopher J. Logothetis. (2003) Foundation for the integration of biologically based therapy in the management of prostate cancer. The Prostate 57:1, 32-38
CrossRef318
J.W Moul, J Anderson, D.F Penson, L.H Klotz, M.S Soloway, C.C Schulman. (2003) Early Prostate Cancer: Prevention, Treatment Modalities, and Quality of Life Issues. European Urology 44:3, 283-293
CrossRef319
Cynthia T. McMurtry, James M. McMurtry. (2003) Metastatic Prostate Cancer: Complications and Treatment. Journal of the American Geriatrics Society 51:8, 1136-1142
CrossRef320
G. van Andel, K.H. Kurth. (2003) The Impact of Androgen Deprivation Therapy on Health Related Quality of Life in Asymptomatic Men with Lymph Node Positive Prostate Cancer. European Urology 44:2, 209-214
CrossRef321
Ashesh B. Jani, Anirban Basu, Ibrahim Abdalla, Phillip P. Connell, Lani Krauz, Srinivasan Vijayakumar. (2003) Impact of Hormone Therapy When Combined With External Beam Radiotherapy for Early-Stage, Intermediate-, or High-Risk Prostate Cancer. American Journal of Clinical Oncology 26:4, 382-385
CrossRef322
M. R. Cooperberg, G. D. Grossfeld, D. P. Lubeck, P. R. Carroll. (2003) National Practice Patterns and Time Trends in Androgen Ablation for Localized Prostate Cancer. JNCI Journal of the National Cancer Institute 95:13, 981-989
CrossRef323
Edward Messing. (2003) The timing of hormone therapy for men with asymptomatic advanced prostate cancer. Urologic Oncology: Seminars and Original Investigations 21:4, 245-254
CrossRef324
John F. Ward, Horst Zincke. (2003) Radical prostatectomy for the patient with locally advanced prostate cancer. Current Prostate Reports 1:1, 5-13
CrossRef325
Harisinghani, Mukesh G., Barentsz, Jelle, Hahn, Peter F., Deserno, Willem M., Tabatabaei, Shahin, van de Kaa, Christine Hulsbergen, de la Rosette, Jean, Weissleder, Ralph, . (2003) Noninvasive Detection of Clinically Occult Lymph-Node Metastases in Prostate Cancer. New England Journal of Medicine 348:25, 2491-2499
Full Text326
BULENT AKDUMAN, E. DAVID CRAWFORD. (2003) The Management of High Risk Prostate Cancer. The Journal of Urology 169:6, 1993-1998
CrossRef327
William K. Oh, Irving D. Kaplan, Philip Febbo, Judith Prisby, Judith Manola, Donald S. Kaufman, Philip W. Kantoff. (2003) Neoadjuvant Doxil Chemotherapy Prior to Androgen Ablation Plus Radiotherapy for High-Risk Localized Prostate Cancer. American Journal of Clinical Oncology 26:3, 312-316
CrossRef328
C.C Parker, D.P Dearnaley. (2003) Radical radiotherapy for prostate cancer. Cancer Treatment Reviews 29:3, 161-169
CrossRef329
John B Fiveash. (2003) Adding androgen suppression to radiotherapy may improve disease-free survival over radiotherapy alone in locally advanced prostate cancer. Cancer Treatment Reviews 29:3, 227-229
CrossRef330
Meric Sengoz, Ufuk Abacioglu, İlknur Cetin, Levent Turkeri. (2003) PSA Bouncing after External Beam Radiation for Prostate Cancer with or without Hormonal Treatment. European Urology 43:5, 473-477
CrossRef331
G MERRICK, K WALLNER, W BUTLER. (2003) Permanent Interstitial Brachytherapy for the Management of Carcinoma of the Prostate Gland. The Journal of Urology 169:5, 1643-1652
CrossRef332
Harrie P. Beerlage. (2003) Alternative therapies for localized prostate cancer. Current Urology Reports 4:3, 216-220
CrossRef333
Nancy B Davis, Ashesh B Jani, Nicholas J Vogelzang. (2003) Selecting a secondary treatment. Urologic Clinics of North America 30:2, 403-414
CrossRef334
Samira Syed, Daniel P. Petrylak, Ian M. Thompson. (2003) Management of high-risk localized prostate cancer: the integration of local and systemic therapy approaches. Urologic Oncology: Seminars and Original Investigations 21:3, 235-243
CrossRef335
Nelson N Stone, Richard G Stock. (2003) Practical considerations in permanent brachytherapy for localized adenocarcinoma of the prostate. Urologic Clinics of North America 30:2, 351-362
CrossRef336
Rajiv S. Samant, Peter B. Dunscombe, Gisele H. Roberts. (2003) A cost-outcome analysis of long-term adjuvant goserelin in addition to radiotherapy for locally advanced prostate cancer. Urologic Oncology: Seminars and Original Investigations 21:3, 171-177
CrossRef337
John F. Ward, Horst Zincke. (2003) Radical prostatectomy for the patient with locally advanced prostate cancer. Current Urology Reports 4:3, 196-204
CrossRef338
David F Penson, Mark S Litwin. (2003) The physical burden of prostate cancer. Urologic Clinics of North America 30:2, 305-313
CrossRef339
Alan Pollack, Eric M Horwitz, Benjamin Movsas, Alexandra L Hanlon. (2003) Mindless or mindful? Radiation oncologists' perspectives on the evolution of prostate cancer treatment. Urologic Clinics of North America 30:2, 337-349
CrossRef340
B. W. Lagerveld, M. P. Laguna, J. J. M. C. H. Rosette. (2003) Long-term results after external beam radiation therapy for T1-T2 localized prostate cancer. Current Urology Reports 4:3, 240-247
CrossRef341
Fritz H Schröder. (2003) Screening for prostate cancer. Urologic Clinics of North America 30:2, 239-251
CrossRef342
Richard E Peschel, John W Colberg. (2003) Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer. The Lancet Oncology 4:4, 233-241
CrossRef343
Kenneth C. Chu, Robert E. Tarone, Harold P. Freeman. (2003) Trends in prostate cancer mortality among black men and white men in the United States. Cancer 97:6, 1507-1516
CrossRef344
ALVARO MARTINEZ, JOSE GONZALEZ, WILLIAM SPENCER, GARY GUSTAFSON, LARRY KESTIN, DAVID KEARNEY, FRANK A. VICINI. (2003) Conformal High Dose Rate Brachytherapy Improves Biochemical Control And Cause Specific Survival in Patients With Prostate Cancer And Poor Prognostic Factors. The Journal of Urology 169:3, 974-980
CrossRef345
Elizabeth C. Kent, Maha H.A. Hussain. (2003) The rationale for adjuvant chemotherapy for high-risk prostate cancer. Current Opinion in Urology 13:2, 123-131
CrossRef346
I Klimberg, D.R Locke, R.A Madore, W.W Smith. (2003) Early prostate cancer: is there a need for new treatment options?. Urologic Oncology: Seminars and Original Investigations 21:2, 105-116
CrossRef347
Dominique Prapotnich, Karim Fizazi, Bernard Escudier, Annick Mombet, Nathalie Cathala, Guy Vallancien. (2003) A 10-Year Clinical Experience with Intermittent Hormonal Therapy for Prostate Cancer. European Urology 43:3, 233-240
CrossRef348
Mark S. Litwin. (2003) Quality of life following definitive therapy for localized prostate cancer: potential impact of multiple therapies. Current Opinion in Urology 13:2, 153-156
CrossRef349
D.W.W Newling. (2003) Early or delayed hormonal therapy in N+ M+ disease. Current Problems in Cancer 27:1, 49-52
CrossRef350
Douglas Scherr, Peter W Swindle, Peter T Scardino. (2003) National Comprehensive Cancer Network guidelines for the management of prostate cancer. Urology 61:2, 14-24
CrossRef351
E.David Crawford. (2003) Early versus late hormonal therapy: debating the issues. Urology 61:2, 8-13
CrossRef352
Holger Borchers, Gerhard Jakse. (2003) How to treat good risk prostate cancer. Current Problems in Cancer 27:1, 40-44
CrossRef353
Howard I. Scher. (2003) Prostate carcinoma. Cancer 97:S3, 758-771
CrossRef354
Mathieu Gutman, Steeve Couillard, Fernand Labrie, Bernard Candas, Claude Labrie. (2003) Effect of treatment sequence with radiotherapy and the antiestrogen EM 800 on the growth of ZR 75 1 human mammary carcinoma in nude mice. International Journal of Cancer 103:2, 268-276
CrossRef355
GARY D. GROSSFELD, DAVID M. LATINI, DEBORAH P. LUBECK, SHILPA S. MEHTA, PETER R. CARROLL. (2003) Predicting Recurrence After Radical Prostatectomy for Patients With High Risk Prostate Cancer. The Journal of Urology157-163
CrossRef356
Katherine F. Croom, Caroline M. Perry. (2003) Leuprolide Acetate. American Journal of Cancer 2:1, 57-64
CrossRef357
Alice K David, Radhika Khwaja, Gary R Hudes. (2003) Treatments for Improving Survival of Patients with Prostate Cancer. Drugs & Aging 20:9, 683-699
CrossRef358
Janet E Brown, Robert E Coleman. (2003) Metastatic Bone Disease. American Journal of Cancer 2:4, 269-281
CrossRef359
GARY D. GROSSFELD, DAVID M. LATINI, DEBORAH P. LUBECK, SHILPA S. MEHTA, PETER R. CARROLL. (2003) Predicting Recurrence After Radical Prostatectomy for Patients With High Risk Prostate Cancer. The Journal of Urology 169:1, 157-163
CrossRef360
G.S. Merrick, W.M. Butler, R.W. Galbreath, J.H. Lief, E. Adamovich. (2003) Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high-risk prostate cancer?. BJU International 91:1, 23-29
CrossRef361
MACK ROACH, JIANDONG LU, MILJENKO V. PILEPICH, SUCHA O. ASBELL, MOHAMMED MOHIUDDIN, DAVID GRIGNON. (2003) Race and Survival of Men Treated for Prostate Cancer on Radiation Therapy Oncology Group Phase III Randomized Trials. The Journal of Urology 169:1, 245-250
CrossRef362
C. Parker, D. Dearnaley. (2003) Hormonal therapy as an adjuvant to radical radiotherapy for locally advanced prostate cancer. BJU International 91:1, 6-8
CrossRef363
Manfred P. Wirth, Michael Froehner. (2003) Value of Endocrine Therapy for Early and Locally Advanced Prostate Cancer. Drugs & Aging 20:2, 115-124
CrossRef364
Brian M Levin, David J Vaughn, Bruce S Malkowicz. (2003) Metastatic Prostate Cancer. American Journal of Cancer 2:2, 87-94
CrossRef365
MACK ROACH, JIANDONG LU, MILJENKO V. PILEPICH, SUCHA O. ASBELL, MOHAMMED MOHIUDDIN, DAVID GRIGNON. (2003) Race and Survival of Men Treated for Prostate Cancer on Radiation Therapy Oncology Group Phase III Randomized Trials. The Journal of Urology245-250
CrossRef366
Lance K Lassiter, Michael A Carducci. (2003) New Approaches for the Prevention of Bone Metastases in Patients with Prostate Cancer. American Journal of Cancer 2:3, 181-199
CrossRef367
R STOCK. (2003) The role of hormonal therapy in prostate brachytherapy. Brachytherapy 2:1, 1-2
CrossRef368
G MERRICK. (2003) The role of hormonal therapy in prostate brachytherapy. Brachytherapy 2:1, 2-4
CrossRef369
Patrick A. Kupelian, Jeffrey C. Buchsbaum, Mohamed Elshaikh, Chandana A. Reddy, Craig Zippe, Eric A. Klein. (2002) Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above. Cancer 95:11, 2302-2307
CrossRef370
M Bolla. (2002) Androgen suppression and irradiation for locally advanced prostate cancer. The Lancet 360:9349, 1987-1988
CrossRef371
Fernand Labrie. (2002) Androgen blockade in prostate cancer in 2002: major benefits on survival in localized disease. Molecular and Cellular Endocrinology 198:1-2, 77-87
CrossRef372
Lyndon M Gommersall, Dickon Hayne, Iqbal S Shergill, Manit Arya, DMA Wallace. (2002) Luteinising hormone releasing hormone analogues in the treatment of prostate cancer. Expert Opinion on Pharmacotherapy 3:12, 1685-1692
CrossRef373
Frank A. Vicini, Alvaro Martinez, Gerald Hanks, Alex Hanlon, Brian Miles, Ken Kernan, David Beyers, Haakon Ragde, Jeffrey Forman, James Fontanesi, Larry Kestin, Gyorgy Kovacs, Louis Denis, Kevin Slawin, Peter Scardino. (2002) An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up. Cancer 95:10, 2126-2135
CrossRef374
Aaron J Milbank, Robert Dreicer, Eric A Klein. (2002) Hormonal therapy for prostate cancer: primum non nocere. Urology 60:5, 738-741
CrossRef375
Francesco Boccardo, Mario Barichello, Michele Battaglia, Giorgio Carmignani, Giancarlo Comeri, Valentino Ferraris, Sergio Lilliu, Franco Montefiore, Filippo Portoghese, Pietro Cortellini, Patrizio Rigatti, Enzo Usai, Alessandra Rubagotti. (2002) Bicalutamide Monotherapy versus Flutamide plus Goserelin in Prostate Cancer: Updated Results of a Multicentric Trial. European Urology 42:5, 481-490
CrossRef376
Tony Y Eng, Charles R Thomas, Terrence S Herman. (2002) Primary radiation therapy for localized prostate cancer. Urologic Oncology: Seminars and Original Investigations 7:6, 239-257
CrossRef377
Mark S Soloway. (2002) Timing of androgen deprivation for prostate cancer: benefits versus side effects—a patient-physician dialogue. Urology 60:5, 735-737
CrossRef378
John M Fitzpatrick, George Blackledge, Don Newling. (2002) PSA—Promoter of Stress and Anxiety or Providentially-Sent Antigen?. European Urology Supplements 1:7, 10-14
CrossRef379
Manfred Wirth, Peter Iversen, David McLeod, William See. (2002) Immediate Therapy in Early Prostate Cancer: Results from the Bicalutamide (‘Casodex’) EPC Programme. European Urology Supplements 1:7, 20-25
CrossRef380
Maxwell V Meng, Gary D Grossfeld, Natalia Sadetsky, Shilpa S Mehta, Deborah P Lubeck, Peter R Carroll. (2002) Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology 60:3, 7-11
CrossRef381
(2002) Discussion following Dr. D’Amico’s presentation. Urology 60:3, 37-38
CrossRef382
David G Mcleod. (2002) Emerging role of adjuvant hormonal therapy. Urology 60:3, 13-20
CrossRef383
(2002) Discussion following Dr. Pollack’s presentation. Urology 60:3, 30-31
CrossRef384
Oliver Sartor. (2002) Endpoints in prostate cancer clinical trials. Urology 60:3, 101-107
CrossRef385
Anthony V. D’Amico. (2002) Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer. Urology 60:3, 32-37
CrossRef386
Alan Pollack, Deborah A Kuban, Gunar K Zagars. (2002) Impact of androgen deprivation therapy on survival in men treated with radiation for prostate cancer. Urology 60:3, 22-30
CrossRef387
W.Robert Lee. (2002) The role of androgen deprivation therapy combined with prostate brachytherapy. Urology 60:3, 39-44
CrossRef388
Peter Iversen. (2002) Antiandrogen monotherapy: indications and results. Urology 60:3, 64-71
CrossRef389
A Zurlo, L Collette, G van Tienhoven, L.E Blank, P Warde, J.B Dubois, W Jeanneret, G Storme, J Bernier, A Kuten, M Pierart, M Bolla. (2002) Acute Toxicity of Conventional Radiation Therapy for High-Risk Prostate Cancer in EORTC Trial 22863. European Urology 42:2, 125-132
CrossRef390
Jackson E. Fowler, Steven A. Bigler, Paige C. White, William L. Duncan. (2002) Hormone Therapy for Locally Advanced Prostate Cancer. The Journal of Urology 168:2, 546-549
CrossRef391
JACKSON E. FOWLER, STEVEN A. BIGLER, PAIGE C. WHITE, WILLIAM L. DUNCAN. (2002) Hormone Therapy for Locally Advanced Prostate Cancer. The Journal of Urology546-549
CrossRef392
Robert Dreicer. (2002) Controversies in the systemic management of patients with evidence of biochemical failure following radical prostatectomy. Cancer Treatment Reviews 28:4, 189-194
CrossRef393
Cora N. Sternberg. (2002) Overview of international collaborative group prostate cancer trials. Critical Reviews in Oncology/Hematology 43:2, 153-158
CrossRef394
William A See. (2002) PSA Changes in Early Prostate Cancer: Implications for Patient Management. European Urology Supplements 1:5, 17-23
CrossRef395
Theo M. de Reijke, Laurence Collette. (2002) EORTC prostate cancer trials: what have we learnt?. Critical Reviews in Oncology/Hematology 43:2, 159-165
CrossRef396
Cora N. Sternberg. (2002) Highlights of contemporary issues in the medical management of prostate cancer. Critical Reviews in Oncology/Hematology 43:2, 105-121
CrossRef397
Gerald W Chodak, Thomas Keane, Laurence Klotz. (2002) Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology 60:2, 201-208
CrossRef398
Anthony V. D'Amico, Richard Whittington, S. Bruce Malkowicz, Kerri Cote, Marian Loffredo, Delray Schultz, Ming-Hui Chen, John E. Tomaszewski, Andrew A. Renshaw, Alan Wein, Jerome P. Richie. (2002) Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 95:2, 281-286
CrossRef399
Judd W. Moul. (2002) Radical prostatectomy versus radiation therapy for clinically localized prostate carcinoma. Cancer 95:2, 211-214
CrossRef400
Anthony V. D'Amico, Tara Saegaert, Ming-Hui Chen, Andrew A. Renshaw, Daniel George, William Oh, Philip W. Kantoff. (2002) Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer. Cancer 95:2, 275-280
CrossRef401
Gregory S. Merrick, Wayne M. Butler, Jonathan H. Lief, Robert W. Galbreath, Edward Adamovich. (2002) Biochemical Outcome for Hormone-Na??ve Patients with High-Risk Prostate Cancer Managed with Permanent Interstitial Br achy therapy and Supplemental External-Beam Radiation. The Cancer Journal 8:4, 322-327
CrossRef402
Katsuyuki Kuratsukuri, Ching Y Wang, Tomomichi Sone, Nobuyasu Nishisaka, Richard F Jones, Gabriel P Haas. (2002) Induction of Antibodies against Prostate-Specific Membrane Antigen (PSMA) by Vaccination with a PSMA DNA Vector. European Urology 42:1, 67-73
CrossRef403
Michel Bolla, Laurence Collette, Léo Blank, Padraig Warde, Jean Bernard Dubois, René-Olivier Mirimanoff, Guy Storme, Jacques Bernier, Abraham Kuten, Cora Sternberg, Johan Mattelaer, José Lopez Torecilla, J Rafael Pfeffer, Carmel Lino Cutajar, Alfredo Zurlo, Marianne Pierart. (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. The Lancet 360:9327, 103-108
CrossRef404
Fernand Labrie, Bernard Candas, Jose-Luis Gomez, Leonello Cusan. (2002) Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?. Urology 60:1, 115-119
CrossRef405
G Sanguineti, S Agostinelli, F Foppiano, P Franzone, S Garelli, M Marcenaro, M Orsatti, V Vitale. (2002) Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma. British Journal of Cancer 86:12, 1843-1847
CrossRef406
(2002) Résumés des présentations du Symposium de Montpellier. Andrologie 12:2, 207-219
CrossRef407
David K Ornstein, Kris E Gaston. (2002) Pharmacotherapy for biochemical recurrences after therapy for localised prostate cancer. Expert Opinion on Pharmacotherapy 3:6, 657-669
CrossRef408
I Pedley. (2002) Transperineal interstitial permanent prostate brachytherapy for carcinoma of the prostate. Surgical Oncology 11:1-2, 25-34
CrossRef409
M Morris. (2002) Novel therapies for the treatment of prostate cancer: current clinical trials and development strategies. Surgical Oncology 11:1-2, 13-23
CrossRef410
Charles M. Bagley, Robert F. Lane, John C. Blasko, Peter D. Grimm, Haakon Ragde, Oliver E. Cobb, Ronald K. Rowbotham. (2002) Adjuvant chemohormonal therapy of high risk prostate carcinoma. Cancer 94:10, 2728-2732
CrossRef411
Ulka Vaishampayan, Maha Hussain. (2002) The evolving role of systemic therapy in high risk prostate cancer: strategies for cure in the 21st century. Critical Reviews in Oncology/Hematology 42:2, 179-188
CrossRef412
E. David Crawford. (2002) Patient Selection for Therapy in Prostate Cancer. European Urology Supplements 1:2, 2-6
CrossRef413
N. Neymark, I. Adriaenssen, T. Gorlia, S. Caleo, M. Bolla. (2002) Estimating survival gain for economic evaluations with survival time as principal endpoint: A cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer. Health Economics 11:3, 233-248
CrossRef414
Annette E Sessions, Edward M Messing. (2002) Timing hormonal therapy in prostate cancer. Urologic Clinics of North America 29:1, 223-227
CrossRef415
S.E.M. Langley, R. Laing. (2002) Prostate brachytherapy has come of age: a review of the technique and results. BJU International 89:3, 241-249
CrossRef416
Basil F El-Rayes, Maha H Hussain. (2002) Hormonal therapy for prostate cancer: past, present and future. Expert Review of Anticancer Therapy 2:1, 37-47
CrossRef417
Tom Pickles, Alex Agranovich, Eric Berthelet, Graeme G. Duncan, Mira Keyes, Winkle Kwan, Michael R. McKenzie, W. James Morris, . (2002) Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma. Cancer 94:2, 362-367
CrossRef418
(2002) Editorial comment. BJU International 89:1, 17-18
CrossRef419
Alfredo Berruti, Marcello Tucci, Carlo Terrone, Gabriella Gorzegno, Roberto M. Scarpa, Alberto Angeli, Luigi Dogliotti. (2002) Background to and Management of Treatment-Related Bone Loss in Prostate Cancer. Drugs & Aging 19:12, 899-910
CrossRef420
Manfred P. Wirth, Michael Froehner. (2002) The Management of Localized or Locally Advanced Prostate Cancer. American Journal of Cancer 1:6, 387-396
CrossRef421
Donald L. Trump. 2002. Prostate Cancer. , 463-473.
CrossRef422
R STOCK, N STONE. (2002) Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer•
. Brachytherapy 1:1, 2-10
CrossRef423
HORST ZINCKE, WEBER LAU, ERIK BERGSTRALH, MICHAEL L. BLUTE. (2001) ROLE OF EARLY ADJUVANT HORMONAL THERAPY AFTER RADICAL PROSTATECTOMY FOR PROSTATE CANCER. The Journal of Urology2208-2215
CrossRef424
Fernando J. Bianco, David P. Wood, Jose Gomes de Oliveira, Jeffrey A. Nemeth, Andrew A. Beaman, Michael L. Cher. (2001) Proliferation of prostate cancer cells in the bone marrow predicts recurrence in patients with localized prostate cancer. The Prostate 49:4, 235-242
CrossRef425
HORST ZINCKE, WEBER LAU, ERIK BERGSTRALH, MICHAEL L. BLUTE. (2001) ROLE OF EARLY ADJUVANT HORMONAL THERAPY AFTER RADICAL PROSTATECTOMY FOR PROSTATE CANCER. The Journal of Urology 166:6, 2208-2215
CrossRef426
Rahul V. Gopalkrishnan, Dong-chul Kang, Paul B. Fisher. (2001) Molecular markers and determinants of prostate cancer metastasis. Journal of Cellular Physiology 189:3, 245-256
CrossRef427
Frank A Vicini, Anthony Abner, Kathy L Baglan, Larry L Kestin, Alvaro A Martinez. (2001) Defining a dose–response relationship with radiotherapy for prostate cancer: is more really better?. International Journal of Radiation Oncology*Biology*Physics 51:5, 1200-1208
CrossRef428
Georgi Pirtskhalaishvili, Ronald L. Hrebinko, Joel B. Nelson. (2001) The Treatment of Prostate Cancer. . Cancer Practice 9:6, 295-306
CrossRef429
Georgi Pirtskhalaishvili, Ronald L. Hrebinko, Joel B. Nelson. (2001) The Treatment of Prostate Cancer. . An Overview of Current Options. Cancer Practice 9:6, 295-306
CrossRef430
Raymond Y. Demers, Ashutosh Tiwari, John Wei, Linda K. Weiss, Richard K. Severson, James Montie. (2001) Trends in the utilization of androgen-deprivation therapy for patients with prostate carcinoma suggest an effect on mortality. Cancer 92:9, 2309-2317
CrossRef431
Smith, Matthew R., McGovern, Francis J., Zietman, Anthony L., Fallon, Mary Anne, Hayden, Douglas L., Schoenfeld, David A., Kantoff, Philip W., Finkelstein, Joel S., . (2001) Pamidronate to Prevent Bone Loss during Androgen-Deprivation Therapy for Prostate Cancer. New England Journal of Medicine 345:13, 948-955
Full Text432
Jackson E Fowler. (2001) Patient-reported experience with the Viadur 12-month leuprolide implant for prostate cancer. Urology 58:3, 430-434
CrossRef433
MICHAEL J. ZELEFSKY, ZVI FUKS, MARGIE HUNT, HENRY J. LEE, DANNA LOMBARDI, CLIFTON C. LING, VICTOR E. REUTER, E. S. VENKATRAMAN, STEVEN A. LEIBEL. (2001) HIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED CONFORMAL RADIOTHERAPY IMPROVES THE OUTCOME OF LOCALIZED PROSTATE CANCER. The Journal of Urology876-881
CrossRef434
Eric A. Klein, Patrick A. Kupelian, Robert Dreicer, David Peereboom, Craig Zippe. (2001) Locally advanced prostate cancer. Current Treatment Options in Oncology 2:5, 403-411
CrossRef435
MICHAEL J. ZELEFSKY, ZVI FUKS, MARGIE HUNT, HENRY J. LEE, DANNA LOMBARDI, CLIFTON C. LING, VICTOR E. REUTER, E.S. VENKATRAMAN, STEVEN A. LEIBEL. (2001) HIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED CONFORMAL RADIOTHERAPY IMPROVES THE OUTCOME OF LOCALIZED PROSTATE CANCER. The Journal of Urology 166:3, 876-881
CrossRef436
Anthony D’Amico. (2001) Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer. Urology 58:2, 78-82
CrossRef437
Hans J Stricker. (2001) Luteinizing hormone–releasing hormone antagonists in prostate cancer. Urology 58:2, 24-27
CrossRef438
Don W.W Newling. (2001) Early versus late androgen deprivation therapy in metastatic disease. Urology 58:2, 50-55
CrossRef439
E.David Crawford. (2001) Editorial comment. Urology 58:2, 150-151
CrossRef440
PATRICK C. WALSH, THEODORE L. DEWEESE, MARIO A. EISENBERGER. (2001) A STRUCTURED DEBATE: IMMEDIATE VERSUS DEFERRED ANDROGEN SUPPRESSION IN PROSTATE CANCER—EVIDENCE FOR DEFERRED TREATMENT. The Journal of Urology 166:2, 508-516
CrossRef441
(2001) Discussion following Dr. Glenn J. Bubley’s presentation. Urology 58:2, 9
CrossRef442
Michael K Brawer, Thomas A Stamey, Jackson Fowler, Michael Droller, Edward Messing, William R Fair. (2001) Perspectives on prostate cancer diagnosis and treatment: a roundtable. Urology 58:2, 135-140
CrossRef443
Steven E. Schild, Thomas M. Pisansky. (2001) THE ROLE OF RADIOTHERAPY AFTER RADICAL PROSTATECTOMY. Urologic Clinics of North America 28:3, 629-637
CrossRef444
Glenn J Bubley. (2001) Is the flare phenomenon clinically significant?. Urology 58:2, 5-9
CrossRef445
Ashesh Jani, Nicholas J. Vogelzang. (2001) RE: NEOADJUVANT HORMONAL ABLATIVE THERAPY BEFORE RADICAL PROSTATECTOMY: A REVIEW. IS IT INDICATED?. The Journal of Urology 166:2, 631
CrossRef446
Anthony V D'Amico. (2001) Combined modality staging for clinically localized adenocarcinoma of the prostate as the basis for patient selection for randomized trials of neoadjuvant chemotherapy. Urologic Oncology: Seminars and Original Investigations 6:4, 171-172
CrossRef447
H. L. Howe, P. A. Wingo, M. J. Thun, L. A. G. Ries, H. M. Rosenberg, E. G. Feigal, B. K. Edwards. (2001) Annual Report to the Nation on the Status of Cancer (1973 Through 1998), Featuring Cancers With Recent Increasing Trends. JNCI Journal of the National Cancer Institute 93:11, 824-842
CrossRef448
Sarah A. Thurman, Naren R. Ramakrishna, Theodore L. DeWeese. (2001) RADIATION THERAPY FOR THE TREATMENT OF LOCALLY ADVANCED AND METASTATIC PROSTATE CANCER. Hematology/Oncology Clinics of North America 15:3, 423-443
CrossRef449
Brian I. Rini, Eric J. Small. (2001) An update on prostate cancer. Current Opinion in Oncology 13:3, 204-211
CrossRef450
Yuzo Furuya, Koichiro Akakura, Masashi Tanaka, Tomohiko Ichikawa, Tatsuo Igarashi, Shino Murakami, Haruo Ito. (2001) Endocrine therapy for recurrence after definitive radiotherapy in patients with prostate cancer. International Journal of Urology 8:5, 222-226
CrossRef451
M Roach III, J Lu, M.V Pilepich, S.O Asbell, M Mohuidden, R Terry, D Grignon, C Lawton, W Shipley, J Cox. (2001) Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. Cancer/Radiothérapie 5:2, 205-205
CrossRef452
Donald L Trump, Joanne A Waldstreicher, Geert Kolvenbag, Paul S Wissel, Blake L Neubauer. (2001) Androgen antagonists: Potential role in prostate cancer prevention. Urology 57:4, 64-67
CrossRef453
P.N. Plowman. (2001) Radical radiation therapy options for organ-confined prostate cancer. BJU International 87:5, 431-440
CrossRef454
W.A. See, D. McLeod, P. Iversen, M. Wirth. (2001) The bicalutamide Early Prostate Cancer Program. Urologic Oncology: Seminars and Original Investigations 6:2, 43-47
CrossRef455
Wolfgang Lilleby, Elisabeth Paus, Eva Skovlund, Sophie D. Foss
CrossRef456
(2001) Diagnosis and management of early prostate cancer. Report of a British Association of Urological Surgeons Working Party. BJU International 83:1, 18
CrossRef457
Fernand Labrie, Alain Bélanger, Van Luu-The, Claude Labrie, Jacques Simard, Sheng-Xiang Lin. 2000. DHEA, The Precursor of Androgens and Estrogens in Peripheral Tissues in the Human: Intracrinology. , 299-342.
CrossRef458
Ron R. Allison, Alan Schulsinger. (2000) Multimodality salvage for patients with persistently elevated postprostatectomy PSA. International Journal of Cancer 90:6, 331-335
CrossRef459
Robert J. Nejat, Hani H. Rashid, Emilia Bagiella, Aaron E. Katz, Mitchell C. Benson. (2000) A PROSPECTIVE ANALYSIS OF TIME TO NORMALIZATION OF SERUM TESTOSTERONE AFTER WITHDRAWAL OF ANDROGEN DEPRIVATION THERAPY. The Journal of Urology 164:6, 1891-1894
CrossRef460
C.C. Schulman, J.E. Altwein, A.R. Zlotta. (2000) Treatment options after failure of local curative treatments in prostate cancer: a controversial issue. BJU International 86:9, 1014-1022
CrossRef461
Robert J. Nejat, Hani H. Rashid, Emilia Bagiella, Aaron E. Katz, Mitchell C. Benson. (2000) A PROSPECTIVE ANALYSIS OF TIME TO NORMALIZATION OF SERUM TESTOSTERONE AFTER WITHDRAWAL OF ANDROGEN DEPRIVATION THERAPY. The Journal of Urology1891-1894
CrossRef462
Steve Burton, Douglas M Brown, Athanasios Colonias, Jeffrey Cohen, Ralph Miller, Gina Rooker, Ronald Benoit, Lori Merlotti, Annette Quinn, Shalom Kalnicki. (2000) Salvage radiotherapy for prostate cancer recurrence after cryosurgical ablation. Urology 56:5, 833-838
CrossRef463
Nancy A. Dawson. (2000) Intermittent androgen deprivation. Current Oncology Reports 2:5, 409-416
CrossRef464
Ulka Vaishampayan, Maha Hussain. (2000) Adjuvant Chemo-/Hormonal Therapy Trials for Locally Advanced Prostate Cancer. Current Oncology Reports 2:5, 402-408
CrossRef465
Reza Z Goharderakhshan, Gary D Grossfeld, Adrienne Kassis, Katsuto Shinohara, Mack Roach, Peter R Carroll. (2000) Additional treatments and reimbursement rates associated with prostate cancer treatment for patients undergoing radical prostatectomy, interstitial brachytherapy, and external beam radiotherapy. Urology 56:4, 622-626
CrossRef466
M. A. Rosenthal. (2000) Advances in the management of prostate cancer. Australian and New Zealand Journal of Medicine 30:5, 593-599
CrossRef467
Bernard Candas, Lionel Cusan, Jose-Luis Gomez, Pierre Diamond, Raul E. Suburu, Jacques L
CrossRef468
Louis Eichel, Edward Messing. (2000) The timing of hormonal treatment for prostate cancer. Current Opinion in Urology 10:5, 403-407
CrossRef469
David E Neal, Jenny L Donovan. (2000) Prostate cancer: to screen or not to screen?. The Lancet Oncology 1:1, 17-24
CrossRef470
M.D. Mason, S. Brewster, L.E. Moffat, P. Kirkbride, R.A. Cowan, P. Malone, M. Sydes, M.K.B. Parmer. (2000) Randomized Trials in Early Prostate Cancer. II: Hormone Therapy and Radiotherapy for Locally Advanced Disease: A Question is Still Unanswered. Clinical Oncology 12:4, 215-216
CrossRef471
ROBERT K. NAM, YOUSSEF ELHAJI, MURRAY D. KRAHN, JALIL HAKIMI, MINNIE HO, WILLIAM CHU, JOAN SWEET, JOHN TRACHTENBERG, MICHAEL A.S. JEWETT, STEVEN A. NAROD. (2000) SIGNIFICANCE OF THE CAG REPEAT POLYMORPHISM OF THE ANDROGEN RECEPTOR GENE IN PROSTATE CANCER PROGRESSION. The Journal of Urology 164:2, 567-572
CrossRef472
Francesco Boccardo. (2000) Hormone therapy of prostate cancer: is there a role for antiandrogen monotherapy?. Critical Reviews in Oncology/Hematology 35:2, 121-132
CrossRef473
ROBERT K. NAM, YOUSSEF ELHAJI, MURRAY D. KRAHN, JALIL HAKIMI, MINNIE HO, WILLIAM CHU, JOAN SWEET, JOHN TRACHTENBERG, MICHAEL A. S. JEWETT, STEVEN A. NAROD. (2000) SIGNIFICANCE OF THE CAG REPEAT POLYMORPHISM OF THE ANDROGEN RECEPTOR GENE IN PROSTATE CANCER PROGRESSION. The Journal of Urology567-572
CrossRef474
F López-Jiménez. (2000) Update in Internal Medicine. Archives of Medical Research 31:4, 329-352
CrossRef475
CrossRef476
Quynh-Thu X. Le, Vivian K. Weinberg, Janice K. Ryu, Pamalar Lewis, Mack Roach. (2000) An Analysis of Patients with Clinically Localized High-Risk Prostate Carcinoma. The Prostate Journal 2:3, 146-156
CrossRef477
J. Fichtner. (2000) The management of prostate cancer in patients with a rising prostate-specific antigen level. BJU International 86:2, 181-190
CrossRef478
Ian D. Cockshott. (2000) Clinical Pharmacokinetics of Goserelin. Clinical Pharmacokinetics 39:1, 27-48
CrossRef479
William K. Oh. (2000) Chemotherapy for patients with advanced prostate carcinoma. Cancer 88:S12, 3015-3021
CrossRef480
Fernand Labrie. (2000) Screening and early hormonal treatment of prostate cancer are accumulating strong evidence and support. The Prostate 43:3, 215-222
CrossRef481
Arnab Chakravatri, Elizabeth M Zehr, Anthony L Zietman, William U Shipley, William B Goggins, Dianne M Finkelstein, Robert H Young, Eric L Chang, Chin-Lee Wu. (2000) Thymosin beta-15 predicts for distant failure in patients with clinically localized prostate cancer—results from a pilot study. Urology 55:5, 635-638
CrossRef482
NELSON N. STONE, RICHARD G. STOCK, PAMELA UNGER, JOHNNY KAO. (2000) Biopsy Results after Real-Time Ultrasound-Guided Transperineal Implants for Stage T 1 -T 2 Prostate Cancer. Journal of Endourology 14:4, 375-380
CrossRef483
Philip J. Walther. (2000) Time for a neoadjuvant chemotherapy strategy in prostate cancer?. Current Opinion in Urology 10:3, 225-227
CrossRef484
(2000) Early Hormonal Therapy in Prostate Cancer. New England Journal of Medicine 342:16, 1215-1216
Full Text485
Richard B. Wilder, Jim Y. Hsiang, Ming Ji, John D. Earle, Ralph deVere White. (2000) Preliminary Results of Three-Dimensional Conformal Radiotherapy as Salvage Treatment for a Rising Prostate-Specific Antigen Level Postprostatectomy. American Journal of Clinical Oncology: Cancer Clinical Trials 23:2, 176-180
CrossRef486
G Duncan. (2000) Report on the quality of life analysis from the phase III trial of pion versus photon radiotherapy in locally advanced prostate cancer. European Journal of Cancer 36:6, 759-765
CrossRef487
BORIS CHERTIN, IRVING M. SPITZ, TZINA LINDENBERG, NURIT ALGUR, TAMI ZER, PETR KUZMA, ALFRED J. MOO YOUNG, RAPHAEL CATANE, AMICUR FARKAS &NA;. (2000) AN IMPLANT RELEASING THE GONADOTROPIN HORMONE-RELEASING HORMONE AGONIST HISTRELIN MAINTAINS MEDICAL CASTRATION FOR UP TO 30 MONTHS IN METASTATIC PROSTATE CANCER. The Journal of Urology838
CrossRef488
Gerald E. Hanks, Alexandra L. Hanlon, Wayne H. Pinover, Eric M. Horwitz, Robert A. Price, Timothy Schultheiss. (2000) Dose selection for prostate cancer patients based on dose comparison and dose response studies. International Journal of Radiation Oncology*Biology*Physics 46:4, 823-832
CrossRef489
BORIS CHERTIN, IRVING M. SPITZ, TZINA LINDENBERG, NURIT ALGUR, TAMI ZER, PETR KUZMA, ALFRED J. MOO YOUNG, RAPHAEL CATANE, AMICUR FARKAS. (2000) AN IMPLANT RELEASING THE GONADOTROPIN HORMONE-RELEASING HORMONE AGONIST HISTRELIN MAINTAINS MEDICAL CASTRATION FOR UP TO 30 MONTHS IN METASTATIC PROSTATE CANCER. The Journal of Urology 163:3, 838-844
CrossRef490
Richard E. Peschel, Theodore J. Robnett, David Hesse, Christopher R. King, Ronald D. Ennis, Peter B. Schiff, Lynn D. Wilson. (2000) PSA based review of adjuvant and salvage radiation therapy vs. observation in postoperative prostate cancer patients. International Journal of Cancer 90:1, 29-36
CrossRef491
Theodore L DeWeese, Danny Y Song. (2000) Current evidence for the role of combined androgen suppression and radiation in the treatment of adenocarcinoma of the prostate. Urology 55:2, 169-174
CrossRef492
Jed M. Pollack. (2000) Radiation Therapy Options in the Treatment of Prostate Cancer. Cancer Investigation 18:1, 66-77
CrossRef493
Gerard C. Morton. (2000) Early prostate cancer. Current Problems in Cancer 24:1, 7-51
CrossRef494
Louis J. Denis, Keith Griffiths. (2000) Endocrine treatment in prostate cancer. Seminars in Surgical Oncology 18:1, 52-74
CrossRef495
Janice A Lyons, Patrick A Kupelian, Dasarahally S Mohan, Chandana A Reddy, Eric A Klein. (2000) Importance of high radiation doses (72 Gy or greater) in the treatment of Stage T1-T3 adenocarcinoma of the prostate. Urology 55:1, 85-90
CrossRef496
Fritz H. Schr
CrossRef497
Messing, Edward M., Manola, Judith, Sarosdy, Michael, Wilding, George, Crawford, E. David, Trump, Donald, . (1999) Immediate Hormonal Therapy Compared with Observation after Radical Prostatectomy and Pelvic Lymphadenectomy in Men with Node-Positive Prostate Cancer. New England Journal of Medicine 341:24, 1781-1788
Full Text498
Gertrude Atkinson, Simon J Hall. (1999) Prodrug activation gene therapy and external beam irradiation in the treatment of prostate cancer. Urology 54:6, 1098-1104
CrossRef499
Jean-Pierre Gerard, Conghua Xie, Christian Carrie, Pascale Romestaing, Pascal Pommier, Francoise Mornex, Sebastien Clippe, Irenee Sentenac, Chantal Ginestet. (1999) CURATIVE EXTERNAL BEAM RADIOTHERAPY FOR PROSTATE CARCINOMA: RESULTS IN 231 PATIENTS TREATED IN LYON. ANZ Journal of Surgery 69:10, 707-711
CrossRef500
Benjamin W Corn, Kathryn Winter, Miljenko V Pilepich. (1999) Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85-31. Urology 54:3, 495-502
CrossRef501
Nicholas J. Hegarty, John M. Fitzpatrick, Jerome P. Richie, Peter T. Scardino, Ralph W. deVere White, Fritz H. Schr
CrossRef502
Koichiro Akakura, Yuzo Furuya, Hiroyoshi Suzuki, Akira Komiya, Tomohiko Ichikawa, Tatsuo Igarashi, Masashi Tanaka, Shino Murakami, Haruo Ito. (1999) External beam radiation monotherapy for prostate cancer. International Journal of Urology 6:8, 408-413
CrossRef503
Koichiro Akakura, Shigeo Isaka, Susumu Akimoto, Haruo Ito, Kiyoki Okada, Takahiko Hachiya, Osamu Yoshida, Yoichi Arai, Michiyuki Usami, Toshihiko Kotake, Ken-Ichi Tobisu, Yasuo Ohashi, Yoshiteru Sumiyoshi, Tadao Kakizoe, Jun Shimazaki. (1999) Long-term results of a randomized trial for the treatment of stages B2 and C prostate cancer: radical prostatectomy versus external beam radiation therapy with a common endocrine therapy in both modalities. Urology 54:2, 313-318
CrossRef504
Brace L. Hintz, James S. Murphy, Jon A. Kaswick, Gary C. Bellman, Christopher J. Ruel, A. Robert Kagan. (1999) Assessment of Relative Tumor Burden in Patients With Clinical T1c Prostate Cancer Treated With Either External Beam or Radical Prostatectomy. American Journal of Clinical Oncology 22:4, 332-337
CrossRef505
Mack Roach. (1999) Finally, good news about prostate carcinoma in African American men. Cancer 86:1, 1-2
CrossRef506
Ronald E. Myers, Gerald W. Chodak, Thomas A. Wolf, Desiree Y. Burgh, Gene T. McGrory, Sue M. Marcus, Julie A. Diehl, Melissa Williams. (1999) Adherence by African American men to prostate cancer education and early detection. Cancer 86:1, 88-104
CrossRef507
Paul Schellhammer. (1999) An update on bicalutamide in the treatment of prostate cancer. Expert Opinion on Investigational Drugs 8:6, 849-860
CrossRef508
Richard G. Stock, Nelson N. Stone. (1999) PERMANENT RADIOACTIVE SEED IMPLANTATION IN THE TREATMENT OF PROSTATE CANCER. Hematology/Oncology Clinics of North America 13:3, 489-501
CrossRef509
M. Roach, D. Forte, M. Alexander. (1999) Re: Race, Prostate Cancer Survival, and Membership in a Large Health Maintenance Organization. JNCI Journal of the National Cancer Institute 91:9, 801-802
CrossRef510
A. S. Robbins, A. S. Whittemore, S. K. Van Den Eeden. (1999) RESPONSE: Re: Race, Prostate Cancer Survival, and Membership in a Large Health Maintenance Organization. JNCI Journal of the National Cancer Institute 91:9, 802-803
CrossRef511
M.Craig Hall, Ralph J Fritzsch, Arthur I Sagalowsky, Allison Ahrens, Beth Petty, Claus G Roehrborn. (1999) Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Urology 53:5, 898-902
CrossRef512
Mack Roach. (1999) Current status of androgen suppression and radiotherapy for patients with prostate cancer. The Journal of Steroid Biochemistry and Molecular Biology 69:1-6, 239-245
CrossRef513
FRANCOIS MEYER, LYNNE MOORE, ISABELLE BAIRATI, YVES FRADET. (1999) DOWNWARD TREND IN PROSTATE CANCER MORTALITY IN QUEBEC AND CANADA. The Journal of Urology 161:4, 1189-1191
CrossRef514
FRANCOIS MEYER, LYNNE MOORE, ISABELLE BAIRATI, YVES FRADET. (1999) DOWNWARD TREND IN PROSTATE CANCER MORTALITY IN QUEBEC AND CANADA. The Journal of Urology1189-1191
CrossRef515
MACK ROACH, JIANDONG LU, MILJENKO V. PILEPICH, SUCHA O. ASBELL, MOHAMMED MOHIUDDIN, ROGER TERRY, DAVID GRIGNON. (1999) LONG-TERM SURVIVAL AFTER RADIOTHERAPY ALONE: RADIATION THERAPY ONCOLOGY GROUP PROSTATE CANCER TRIALS. The Journal of Urology 161:3, 864-868
CrossRef516
MACK ROACH, JIANDONG LU, MILJENKO V. PILEPICH, SUCHA O. ASBELL, MOHAMMED MOHIUDDIN, ROGER TERRY, DAVID GRIGNON. (1999) LONG-TERM SURVIVAL AFTER RADIOTHERAPY ALONE. The Journal of Urology864-868
CrossRef517
Lee, Warde, Jewett. (1999) Neoadjuvant hormonal therapy in carcinoma of the prostate. BJU International 83:4, 438-448
CrossRef518
LOUIS L. PISTERS, COLIN P. N. DINNEY, CURTIS A. PETTAWAY, SHELLIE M. SCOTT, R. JOSEPH BABAIAN, ANDREW C. von ESCHENBACH, PATRICIA TRONCOSO. (1999) A FEASIBILITY STUDY OF CRYOTHERAPY FOLLOWED BY RADICAL PROSTATECTOMY FOR LOCALLY ADVANCED PROSTATE CANCER. The Journal of Urology509-514
CrossRef519
Fernand Labrie, Bernard Candas, Andr
CrossRef520
LOUIS L. PISTERS, COLIN P.N. DINNEY, CURTIS A. PETTAWAY, SHELLIE M. SCOTT, R. JOSEPH BABAIAN, ANDREW C. von ESCHENBACH, PATRICIA TRONCOSO. (1999) A FEASIBILITY STUDY OF CRYOTHERAPY FOLLOWED BY RADICAL PROSTATECTOMY FOR LOCALLY ADVANCED PROSTATE CANCER. The Journal of Urology 161:2, 509-514
CrossRef521
JAN ADOLFSSON, GUNNAR STEINECK, PER OLOV HEDLUND. (1999) DEFERRED TREATMENT OF LOCALLY ADVANCED NONMETASTATIC PROSTATE CANCER. The Journal of Urology505-508
CrossRef522
JAN ADOLFSSON, GUNNAR STEINECK, PER OLOV HEDLUND. (1999) DEFERRED TREATMENT OF LOCALLY ADVANCED NONMETASTATIC PROSTATE CANCER: A LONG-TERM FOLLOWUP. The Journal of Urology 161:2, 505-508
CrossRef523
(1999) Diagnosis and management of early prostate cancer. Report of a British Association of Urological Surgeons Working Party. BJU International 83:1, 18-33
CrossRef524
David M Preston, John J Bauer, Roger R Connelly, Timothy Sawyer, John Halligan, Eric S Leifer, David G McLeod, Judd W Moul. (1999) Prostate-specific antigen to predict outcome of external beam radiation for prostate cancer: walter reed army medical center experience 1988–1995. Urology 53:1, 131-138
CrossRef525
Eric M. Horwitz, Alexandra L. Hanlon, Wayne H. Pinover, Gerald E. Hanks. (1999) Is there a role for short-term hormone use in the treatment of nonmetastatic prostate cancer?. Radiation Oncology Investigations 7:4, 249-259
CrossRef526
CrossRef527
Richard E. Peschel, Zhe Chen, Kenneth Roberts, Ravinder Nath. (1999) Long-term complications with prostate implants: Iodine-125 vs. palladium-103. Radiation Oncology Investigations 7:5, 278-288
CrossRef528
Roger Kirby. (1998) Treatment options for early prostate cancer. Urology 52:6, 948-962
CrossRef529
M. Colombel, F. Blanc, J. M. Marechal. (1998) Le cancer de la prostate: Acquis et challenges pour l'an 2000. Andrologie 8:4, 373-382
CrossRef530
Anthony V. D'Amico, April Desjardin, Ming-Hui Chen, Steve Paik, Delray Schultz, Andrew A. Renshaw, Kevin R. Loughlin, Jerome P. Richie. (1998) Analyzing outcome-based staging for clinically localized adenocarcinoma of the prostate. Cancer 83:10, 2172-2180
CrossRef531
David K. Ornstein, Joseph Oh, Jonathan D. Herschman, Gerald L. Andriole. (1998) EVALUATION AND MANAGEMENT OF THE MAN WHO HAS FAILED PRIMARY CURATIVE THERAPY FOR PROSTATE CANCER. Urologic Clinics of North America 25:4, 591-601
CrossRef532
D. Kirk. (1998) Prostate cancer in the elderly. European Journal of Surgical Oncology (EJSO) 24:5, 379-383
CrossRef533
S.D. Pathak, P.D. Grimm, V. Chalana, Yongmin Kim. (1998) Pubic arch detection in transrectal ultrasound guided prostate cancer therapy. IEEE Transactions on Medical Imaging 17:5, 762-771
CrossRef534
A.J. Dowling, I.F. Tannock. (1998) Systemic treatment for prostate cancer. Cancer Treatment Reviews 24:4, 283-301
CrossRef535
Wolfgang Hinkelbein. (1998) Adjuvante oder therapeutische Androgensuppression beim lokoregionär fortgeschrittenen Prostatakarzinom (RTOG 85-31). Strahlentherapie und Onkologie 174:7, 385-386
CrossRef536
D.M Herold, A.L Hanlon, B Movsas, G.E Hanks. (1998) Age-Related Prostate Cancer Metastases. Urology 51:6, 985-990
CrossRef537
TORVALD GRANFORS, HANS MODIG, JAN-ERIK DAMBER, RADISA TOMIC. (1998) COMBINED ORCHIECTOMY AND EXTERNAL RADIOTHERAPY VERSUS RADIOTHERAPY ALONE FOR NONMETASTATIC PROSTATE CANCER WITH OR WITHOUT PELVIC LYMPH NODE INVOLVEMENT: A PROSPECTIVE RANDOMIZED STUDY. The Journal of Urology 159:6, 2030-2034
CrossRef538
TORVALD GRANFORS, HANS MODIG, JAN-ERIK DAMBER, RADISA TOMIC. (1998) COMBINED ORCHIECTOMY AND EXTERNAL RADIOTHERAPY VERSUS RADIOTHERAPY ALONE FOR NONMETASTATIC PROSTATE CANCER WITH OR WITHOUT PELVIC LYMPH NODE INVOLVEMENT. The Journal of Urology2030-2034
CrossRef539
Alan Pollack, Gunar K. Zagars. (1998) Androgen ablation in addition to radiation therapy for prostate cancer: Is there true benefit?. Seminars in Radiation Oncology 8:2, 95-106
CrossRef540
Jackson E. Fowler, Steven A. Bigler, John M. Kolski, David T. Yee. (1998) Early results of a prospective study of hormone therapy for patients with locally advanced prostate carcinoma. Cancer 82:6, 1112-1117
CrossRef541
Anthony V. D'Amico, Mitchell Schnall, Richard Whittington, S.Bruce Malkowicz, Delray Schultz, John E. Tomaszewski, Alan Wein. (1998) Endorectal coil magnetic resonance imaging identifies locally advanced prostate cancer in select patients with clinically localized disease. Urology 51:3, 449-454
CrossRef542
Anthony V. D'Amico, Eric Chang, Mark Garnick, Phillip Kantoff, Michael Jiroutek, Clare M. Tempany. (1998) Assessment of prostate cancer volume using endorectal coil magnetic resonance imaging: a new predictor of tumor response to neoadjuvant androgen suppression therapy. Urology 51:2, 287-292
CrossRef543
David Hodgson, Padraig Warde, Mary Gospodarowicz. (1998) The management of locally advanced prostate cancer. Urologic Oncology: Seminars and Original Investigations 4:1, 3-12
CrossRef544
(1997) Treatment of Prostate Cancer with Goserelin and Radiotherapy. New England Journal of Medicine 337:23, 1693-1694
Full Text545
P BEY. (1997) Indications et résultats de la radiothérapie exclusive dans les formes précoces d'adénocarcinome prostatique. Cancer/Radiothérapie 1:5, 431-438
CrossRef546
Blasko, John C., Lange, Paul H., . (1997) Prostate Cancer — The Therapeutic Challenge of Locally Advanced Disease. New England Journal of Medicine 337:5, 340-341
Full Text547
(1997) The Emerging Role of Neoadjuvant Hormonal Therapy in the Management of Localized Prostatic Cancer-Reply. Cancer Investigation 15:6, 614-616
CrossRef
- Letters
